EP PerMed
European Partnership
for Personalised Medicine

EUROPEAN PARTNERSHIP

Joint Transnational Call for Proposals (2027) for

Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)

(EP PerMed Grant 101137129)

Guidelines for Applicants

Important Deadlines

Submission of pre-proposals: 20 January 2027 at 14:00 (CET)
Submission of invited full proposals: 25 May 2027 at 14:00 (CEST)

Link to the electronic proposal submission tool:
https://ptoutline.eu/app/eppermed2027

For further information, please visit our website: **www.eppermed.eu**

or contact the EP PerMed Joint Call Secretariat (JCS)

French National Research Agency (ANR)
86 rue Regnault, 75013 Paris, FRANCE

Mylène Vaillancourt, Dr. Mérick Machouri
Phone: +33 1 78 09 80 36, +33 1 72 73 06 72

Email: EPPerMed@anr.fr

Co-funded by
the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

Table of contents

1 Background **5**

2 Electronic application system **5**

3 Proposal submission **6**

3.1 Whom to contact during the application process 7

4 Eligible annexes in the pre- and full proposal stage **7**

5 Fostering multidisciplinary teams and intersectoral collaboration to support Personalised Medicine development **8**

6 Patient and citizen involvement **9**

6.1 Funding for Patient/citizen organisations 9

7 Inclusion of sex, gender analysis/research or underrepresented populations **10**

7.1 Sex and gender representation 10

7.2 Underrepresented populations 10

8 Preclinical development and Chemistry, Manufacturing, and Controls **11**

9 Scientific Data Open Access Policy **12**

10 General Data Protection Regulation **13**

11 Building your proposals **13**

12 Annex I: List of National Contacts **17**

13 Annex II: Guidelines for Organisations representing Patients or Citizens **21**

14 Annex III: Information for applicants concerning regional/national eligibility criteria **24**

Austria 24

Belgium (Flanders, FWO) 27

Belgium (Flanders, FIO/VLAIO) 28
Belgium (Wallonia-Brussels Federation) 29
Belgium (Wallonia) 31
Canada 32
Czech Republic 35
Estonia (EIS) 39
Estonia (ETAG) 41
Finland 44
France 45
Germany (BMFTR) 48
Germany (BMG) 50
Germany (Saxony) 52
Greece 53
Hungary 54
Ireland 56
Israel (CSO-MOH) 59
Israel (IIA) 61
Italy (IT-MoH) 62
Italy (Friuli Venezia Giulia) 65
Italy (Lombardy) 68
Italy (Tuscany) 71
Latvia 73
Lithuania 76
Luxembourg 79
Norway 81
Poland 83
Portugal (FCT) 89
Portugal (Azores) 90
Romania 92

Slovak Republic 94

Spain (ISCIII) 98

Spain (Andalusia) 104

Spain (Catalonia) 106

Sweden (SRC) 107

Sweden (VINNOVA) 109

The Netherlands 111

Türkiye 116

1 Background

The **European Partnership for Personalised Medicine, EP PerMed**, is a platform for joint programming of national and European regional research and innovation (R&I) programmes putting into action "The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023)"[1], **SRIA for PM (2023)**, through dedicated research, development and innovation funding. The funding of transnational collaborative research is a joint activity to further enhance the cooperation between stakeholders across Europe and beyond to maximise the benefits of personalised medicine (PM) approaches and thus pooling resources and achieving investments of scale in this field.

To align regional and national research strategies and funding activities, promote excellence, reinforce the competitiveness of European players in PM research, while fostering collaboration within Europe, and enhancing European collaboration with non-EU countries, 39 funding organisations have agreed to launch this Joint Transnational Call (JTC) 2027 for collaborative innovative research projects in PM cofunded by the European Union (EU). The funding organisations participating in this call particularly wish to promote innovative, interdisciplinary collaboration and to encourage translational research proposals in human health.

The JTC2027 funds research projects that aim to develop and validate innovative and novel Cell and Gene Therapies (CGT) for PM, using at least one of the following approaches: 1) Somatic cell therapeutics (e.g., in the form of stem cells, organoids, or cells of the immune system), 2) Gene therapeutics in the form of gene substitution, addition or suppression therapies using viral and non-viral vectors or genome editing, 3) Combined cell and gene therapeutics, in the form of genetically modified cells, 4) Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles as vehicle for gene-based therapeutic procedure. Accompanying the above research fields, proposals may include 1) diagnostic approaches to enable patient stratification or predict response, efficacy, dosage optimisation, adverse effects or toxicity, 2) development of novel manufacturing or delivery methods provided they incorporate a personalised CGT backbone, 3) preclinical in vitro/in vivo characterisation assays for novel and personalised CGT, to assess key aspects such as batch-to-batch consistency, biodistribution, potency, stability, safety and tolerability. Please read the call text for further details.

2 Electronic application system

Research project consortia who intend to submit a transnational proposal must register at **https://ptoutline.eu/app/eppermed2027**, click on "sign up" and complete the different sections following the instructions.

There must be **only one application per project**. The coordinator's and all partners' information must be filled in the same application.

[1] **https://www.eppermed.eu/action-areas/sria/**

3 Proposal submission

Before submitting, make sure your consortium complies with:

- the **central eligibility criteria** (see Call text section 7);
- the **regional/national eligibility and budgetary criteria** (see Annex III of this document).

There is a two-step procedure for joint applications consisting of a pre-proposal stage (open to all) and a full proposal stage (by invitation only). In both stages, **one joint proposal** (in English) shall be prepared by the partners of a joint transnational consortium and submitted by the coordinator, by uploading it on the electronic submission system: **https://ptoutline.eu/app/eppermed2027**.

The pre-proposal template is provided on the EP PerMed JTC webpage: **https://www.ep-permed.eu/funding-projects/calls/jtc2027**. The full proposal form will be sent by the Joint Call Secretariat to coordinators *if* invited to submit a full proposal in the second stage.

Only proposals using the official templates will be accepted.

In both stages, all fields must be completed, and the format and length of each section must be respected using the following specifications:

- **Page size:** DIN-A4
- **Font & size**: Segoe UI 10
- **Space:** single-spaced

Submission consists of two parts:

1) The pre- or full proposal template, provided in Word format, to describe the planned work.
2) The electronic application used to provide partners' information and financial plans.

Both parts must be submitted in due time and indications provided must be identical (e.g. budgets, names of principal investigators or funding agencies). In case of inconsistencies between the information registered in the electronic submission system and the information included in the PDF of the application form, the information registered in the submission tool shall prevail.

Proposals need to be signed (either digitally or with a scanned version of the original signature page) and uploaded in a PDF format to the electronic submission tool (must not exceed 8 Megabytes). Proposals exceeding these limitations will be rejected.

Annexes must be uploaded as separate files (PDF) in the electronic submission system.

Deadline to submit pre-proposals: **20 January 2026 (14:00, CET)**

Deadline to submit full proposals: **25 May 2026 (14:00, CEST)**

After these deadlines, the electronic submission system will not accept proposals and it will not be possible to amend the proposal or to add further documents. Applications submitted by email will not be accepted.

Please note: The electronic submission system may be overloaded on the day of the deadline. Therefore, it is recommended to complete the online forms and upload the proposal in proper time.

Additional mandatory documents:

Applicants from certain regions/countries **may be required to submit** the proposal or other information directly to their relevant regional/national funding organisations (in some cases even **before the deadline of this call)**. Therefore, applicants are strongly advised to **verify regional/national-specific funding organisation regulations and other specific information** (see Annex III of this document).

3.1 Whom to contact during the application process

For any questions and additional information, please contact the Joint Call Secretariat or your respective funding organisations contact person (see Annex I of this document).

Joint Call Secretariat
will answer questions referring to:

- General (central) eligibility
- Technical issues during proposal submission
- Rebuttal step
- Redress appeals
- Modifications between the pre- and full proposals

Regional/national funding organisations
will answer questions related to:

- Specific regional/national eligibility
- Requested budget and eligible costs
- ANY specific regional/national requirement for proposal submission

4 Eligible annexes in the pre- and full proposal stage

The following annexes are eligible. It is indicated in brackets at which stage the documents have to be provided. All annexes are to be uploaded as separate files (not as annex to the proposal forms) via the electronic submission system:

- Annex 1 – Ethical self-assessment (**mandatory**), at full proposal stage – the template is provided with the full proposal form;
- Annex 2 – Description of eligible career breaks for Early Career Researchers and ECR dedicated supporting letters (if any; free format, at every stage);
- Annex 3 – Description of Animal Research Projects (if any), at full proposal stage – the template is provided with the full proposal form;
- Annex 4 – Letter of commitment for a project partner participating on own funds (if any; free format, at every stage; mandatory in the full proposal stage);
- Annex 5 – Supporting letters (at every stage) or endorsement letters (at every stage) in free format (if any);
- Annex 6 – The patient's/citizen's involvement plan (**mandatory** if funding is requested from EP PerMed to clarify the eligibility of funds in the pre- and full proposal stage).

5 Fostering multidisciplinary teams and intersectoral collaboration to support Personalised Medicine development

Despite recent progress in the PM field, many challenges remain. The development of PM approaches is complex, as several determinants are interlinked and many still not identified. It requires a truly cross-sectoral and multidisciplinary collaboration, including stakeholders from preclinical and clinical research, bioinformatics, Ethical, Legal and Social Aspects (ELSA) research, implementation research, health economics research, actors from the public and private sector, and end-users (or experts that can support research on the impact for end-users). Consortia funded in this EP PerMed call are required to be interdisciplinary and trans-sectoral. Research teams forming a consortium should include investigators from a broad range of relevant scientific disciplines, research fields or sectors, and bring together the necessary expertise to achieve the objectives as well as expected impact of the research proposed, i.e. (please note: this call is not limited to those examples):

- **Preclinical research:** Efforts are needed to increase the understanding of the complexity of relevant disease pathogeneses, to develop suitable preclinical models/platforms and to support the identification of the most significant potential treatment strategies.
- **Clinical research:** The translation of research from bench to bedside and a more circular approach to research and development is essential. This includes the progress of promising discoveries from academic research to the clinical research stage, further development into viable products by the private sector, and the implementation in healthcare.
- **Bioinformatics or Health Informatics:** Bioinformatics/data research supports method and technology development, e.g. the development of multi-modal and Artificial Intelligence-driven algorithms to predict medication efficacy and adverse effects. Developed approaches should have the potential to be translated to large cohorts, e.g. different age groups, genetic/omic backgrounds, including ethnic minorities, or different socio/economic conditions.
- **ELSA research/Implementation research:** ELSA research, or implementation research, addresses societal and ethical issues of PM, e.g. developing methods for ethically dealing with personal data, fair access to new or often expensive diagnostic tools or treatments for prevention and therapies, or availability of decision support tools for healthcare providers. This could include research aiming to avoid bias by automated decision supporting tools, research on suitable regulatory approaches for diagnostics and development of tailored treatments, as well as research on fundamental societal challenges and the integration of the patient's and citizen's needs, connected to autonomous, informed decision-making.
- **Health economics research:** The integration of health economics research allows consortia to develop new or evolve already existing health economic models to enable an effective early-prediction of cost-effectiveness or socioeconomic impact of tailor-made PM approaches and to facilitate therewith decisions on future implementation in healthcare.

The proposal should describe which formats and methods will be used for stakeholder consultation and for analysis of consultation results, and it should describe how consultation results are fed back into the overall progress of the project

6 Patient and citizen involvement

Involving patients and citizens representatives in research projects from the onset can improve quality and relevance for example by:

- Providing a different and complementary perspective;
- Encouraging the use of clear and accessible language, and content of information in documents provided to the wider public;
- Helping to ensure that the methods proposed for the study are suitable and sensitive to the situations of potential research participants;
- Helping to ensure that the research considers outcomes that are important to the patients and the public.
- Helping to ensure that research outcomes are shared and accessible to the public.

In addition, involving members of the public ensures that research considers broader principles of citizenship, accountability and transparency.

Consortia submitting proposals to this call are asked to describe the patient/citizen involvement throughout the various stages of the research design, planning, conduct/implementation, analysis and dissemination and utilisation of the results. Applicants should employ patient engagement and co-creation methods appropriate to the research objectives and target population, which may include patient advisory boards, interviews, focus groups, co-design workshops, patient journey mapping, patient preference studies, etc. The extent of citizen/patient involvement may vary depending on the context of the study proposed. If a consortium does not deem patient/citizen involvement to be reasonable given their project aims and methods, this should be explained and justified.

The involvement of patient/citizen organisations in research proposals submitted is part of the evaluation (see Call Text section 8 C. Evaluation criteria).

6.1 Funding for Patient/citizen organisations

Patient/citizen representing organisations have the possibility to participate as full consortium partners either by requesting funding through one of the following funding mechanisms, or on own funds.

EP PerMed central funding:

EP PerMed is financially supporting patient/citizen organisations as full consortium partners. Funds are limited to a total of 50,000 € per consortium, for maximum 2 patient/citizen organisations per consortium and over 3 years. The development of a patient's/citizen's involvement plan (to be uploaded electronically as **Annex 6 of the application forms**) is **mandatory** to verify the eligibility of patient/citizen organisations to receive funding from EP PerMed (see Annex II of this document for eligibility criteria).

Regional/national funding organisations:

Patient/citizen organisations may apply for funding through regional/national funding organisations, if eligible according to the respective funding regulations (see Annex III of this document).

Patient/citizen organisations can participate on own funds:

Indications concerning the financial commitment (*in-kind*) of the patient/citizen organisation participating in the project on own funds must be provided in the proposal budget table as well as in the online submission tool **PT-Outline**.

7 Inclusion of sex, gender analysis/research or underrepresented populations

7.1 Sex and gender representation

To promote gender equality in research and innovation, applicants are **required to integrate sex and gender considerations into their research**. Sex and gender considerations include two main aspects: the **inclusion of sex or gender research** *per se*, and the **sex distribution of research teams and the distribution of roles** in a consortium (gender balance).

Inclusion of sex aspects in the research content:

A growing body of evidence demonstrates system-wide (cardiovascular, immune, neurological, etc.) sex and gender differences in clinical disorders and therapeutic interventions, including differences in severity, mechanisms, and treatment response, even when the prevalence is similar between men and women. Analysing and considering the differences between men/males and women/females in the research and innovation content of the projects **must then be integrated in the proposals**.

Sex and gender balance in research teams:

Sex and gender balance in research teams helps create an equitable work environment where everyone can thrive, while also making research more relevant and responsive to society. The **sex and gender balance among researchers with a leading role** in consortia submitting a proposal to an EP PerMed call is also assessed in the evaluation of proposals (see Call Text section 8 C. Evaluation criteria).

7.2 Underrepresented populations

Applicants are also strongly encouraged to consider underrepresented populations (e.g. ethnic minorities), or underrepresented patient sub-groups, e.g. children or elderly, as well as social components, e.g. different economic, educational backgrounds, in proposals submitted to the EP PerMed call. A project is considered relevant when it concerns individuals or groups of people or when its findings may affect individuals or groups. The **inclusion of underrepresented populations** analysis is assessed in the evaluation of proposals (see Call text section 8 C. Evaluation criteria).

8 Preclinical development and Chemistry, Manufacturing, and Controls

Compared to conventional therapies, CGT face distinct biological, manufacturing, and commercial challenges, e.g. heterogeneity in donor cells or between cell batches, small batch size, potency and stability, vein-to-vein time, etc. These challenges need to be considered early in the development to maximise the likelihood of successful translation into clinical trials and implementation. Preclinical development and early Chemistry, Manufacturing, and Controls (CMC) strategies for CGT are not only about late-stage compliance, but about building a development strategy that is scalable, sustainable, repeatable and robust from the start.

While proposals funded under this call are not expected to deliver fully regulatory-ready innovations, they are **required to include a dedicated work package addressing preclinical development and early CMC for the proposed** CGT (see also Call Text, section 5).

Preclinical development aspects:

Preclinical development includes studies to characterise the pharmacology, biodistribution, and toxicology of a new medicinal product. There is no single standardised plan for medicinal product development, and each plan must be adapted to the product being developed. In the early phases of development, preliminary safety and toxicology tests do not require conformity with Good Laboratory Practice (GLP) principles. However, these exploratory assays are essential for the initial decision making regarding a new substance, and will affect the planning of preclinical regulatory assays that will be performed prior to clinical authorisation. CGT preclinical development aspects include:

- **Pharmacology**: e.g. expansion kinetics, persistence, mechanism of action, clearance, pharmacodynamics markers, dose–response, safety pharmacology;
- **Biodistribution**: e.g. trafficking, homing, non-target distribution, persistence in compartments;
- **Toxicology**: e.g. immune response, side effects, on-target/off-tumour toxicity, genotoxicity, reproductive/developmental toxicity, general toxicology, dose-limiting or high-dose toxicity.

Chemistry, Manufacturing, and Controls aspects:

CMC includes an early assessment of the feasibility of GMP-compliant manufacture and a prospective manufacturing strategy. This may include the identification and preliminary suitability assessment of a GMP manufacturing facility or external manufacturing partner. For CGT, process development and the control strategy should be linked to a credible pathway towards GMP-compliant manufacture of the investigational medicinal product. Depending on the project's maturity, this should address raw and starting materials, release testing, potency, stability and hold times, storage and transport, chain of identity and chain of custody, and comparability.

- **Target Product Profile:** Strategic document defining the characteristics of a product to guide the development of safe and effective medical products. It includes the intended indication, patient population, dosing strategy, quality, safety and efficacy, considering e.g., the route of administration, dosage form, bioavailability, strength, and stability.

- **Critical Quality Attributes:** Critical quality attributes is used to determine which characteristics (e.g. identity, purity, potency, etc.) impact safety and efficacy and must be controlled to ensure product quality.
- **Manufacturing process:** Conceptual mapping of the manufacturing process helps defining the full workflow, from starting materials (e.g., donor cells, plasmids), through key processing steps (e.g., isolation, transduction, editing, expansion), to final formulation and storage. At an early stage, this exercise enables the identification of potential risks and bottlenecks in the process.
- **Scalable process strategy:** Considering, from an early stage, the use of platform technologies (e.g., standardised vectors, cell expansion systems), as well as automation and closed systems, can significantly increase process robustness, reproducibility, and scalability. Scalability may also include the identification and preliminary suitability assessment of a GMP manufacturing facility or external manufacturing partner. Planning and conducting small-scale experiments that mimic future manufacturing conditions can help anticipate technical challenges and de-risk process development.
- **Process Risk Assessment:** Risk assessment is a valuable science-based process used to identify parameters (e.g., process, equipment, input materials) with potential to have an impact on product quality, based on prior knowledge and initial experimental data. Risk assessment also includes identifying critical materials and evaluating GMP availability and supplier reliability.
- **Analytical and Characterisation:** Thorough characterisation is essential to support the development of a robust control strategy and to ensure consistent product quality standards. Early identification and development of appropriate analytical methods will help achieving comprehensive product understanding, including identity, purity, potency, and safety attributes. These methods should evolve from exploratory tools to more robust, fit-for-purpose assays as development progresses. The control strategy should be linked to a credible pathway towards GMP-compliant manufacture of the investigational medicinal product.

9 Scientific Data Open Access Policy

Applicants must clearly describe all tools, technologies, and digital supports to be used in the project, as well as the methodological approach. In addition, descriptions should be included of how data from different sources (such as different institutions) will be combined, how different data streams will be merged and how the primary outcomes will be meaningful across different institutions. Proposals should explain how the data, tools, code or algorithms gathered, developed or used through the project will be maintained after the project end and would be available (findable, accessible, interoperable and re-usable) or communicated to the wider research community, during and after the end of the project period.

In addition, EP PerMed requires projects selected for funding to develop a data management plan (DMP). DMPs must comply with international state-of-the-art standards for data security [following

the **FAIR principles**[2]**, the General Data Protection Regulation (GDPR)**[3] **and in accordance with Ethical principles**[4] **for data management**].

10 General Data Protection Regulation

The following Data Privacy Notice applies:

By applying to the call, applicants consent to the use, processing and retention of their data provided during application, in line with the above notice and for the purposes of:

- processing and evaluating the application where processing shall be lawful - only if and to the extent that - processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller;
- administering any subsequent funding award;
- managing the funding organisation's relationship with them;
- analysing and evaluating the call;
- reporting to the European Commission/ European Health and Digital Executive Agency (HaDEA) on the call;
- providing aggregate data to regional/national and European surveys and analyses;
- complying with audits that may be initiated by the funding organisations.

The members of the EP PerMed consortium may share an applicant's data with third parties (some of which may be based outside the European Economic Area) in relation to the above activities including evaluators, auditors and the European Commission (or its agencies).

The members of the EP PerMed consortium may link the data that applicants provide in the application with regional/national, bibliographic or external research funding data which is available through public subscription-based databases (e.g. Scopus, Web of Science, etc.) or other regional, national or open datasets. The members of the EP PerMed consortium may also link the data that applicants provide in their application with future data that applicants provide as part of the ongoing management and reporting.

Data on funding organisations including contact details of Call Steering Committee[5] members are kept for the purpose of the call communication. The information will be published with prior consent of the respective management bodies.

11 Building your proposals

Please take note of the references below that could be helpful:

---

[2] findable, accessible, interoperable and reusable (FAIR): **http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-data-mgt_en.pdf**

[3] **https://gdpr-info.eu/**

[4] **http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/ethics/h2020_hi_ethics-data-protection_en.pdf**

[5] Call Steering Committee: comprises a single representative from each country's/region's funding organisation

- **Partnering** options: The partnering tool, supported by EP PerMed, provides a platform for interested users to search for collaboration partners: **https://www.b2match.com/e/eppermed-partnering**
- European **Research Infrastructures/Platforms**:
  - Biobanking and Biomolecular Resources Research Infrastructure (BBMRI): **https://www.bbmri-eric.eu/**
  - The European Life Sciences Infrastructure for Biological Information (ELIXIR): **https://elixir-europe.org/**
  - European Infrastructure for translational medicine (EATRIS): **http://eatris.eu/**
  - European Clinical Research Infrastructure Network (ECRIN): **http://www.ecrin.org/**
  - European High Capacity Screening Network (EU-Openscreen): **http://www.eu-openscreen.eu/**
  - European Infrastructure for Phenotyping, Archiving and Distribution of Mouse Models (INFRAFRONTIER): **https://www.infrafrontier.eu/**
  - Integrated Structural Biology Infrastructure for Europe (INSTRUCT): **https://instruct-eric.org/**
  - European Strategy Forum on Research Infrastructures (ESFRI): **https://www.esfri.eu/**
  - The European Intergovernmental Research Organisation forum (EIROforum): **https://www.eiroforum.org/about-eiroforum/**
  - Coordinated Research Infrastructures Building Enduring Life-science Services (CORBEL): **http://www.corbel-project.eu/services.html**
- Open access, gender equality, science education, ethics and good governance:
  - Gender equity in research and innovation: **https://research-and-innovation.ec.europa.eu/strategy/strategy-research-and-innovation/democracy-and-rights/gender-equality-research-and-innovation_en#gender-equality-in-horizon-europe**
  - Canadian Institute of Health Research "Online Training Modules: Integrating Sex & Gender in Health Research": **http://www.cihr-irsc.gc.ca/e/49347.html**
  - the Responsible Research and Innovation site of the European Commission: **https://caixaresearch.org/en/caixaresearch-rri-tools**
  - The Societal Readiness Thinking Tool – Guide for the steps of including RRI in a project: **https://thinkingtool.eu/**
  - EC Guide "How to complete your ethics self-assessment": **https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/how-to-complete-your-ethics-self-assessment_en.pdf**
- Guidelines for Animal Research Projects:
  - PREPARE guidelines (Planning Research and Experimental Procedures on Animals: Recommendations for Excellence): **https://norecopa.no/PREPARE**
  - ARRIVE guidelines (Animal Research: Reporting of *In Vivo* Experiments): **https://arriveguidelines.org/arrive-guidelines**

- Recommendations concerning the involvement of competent authorities in research projects: **https://www.hma.eu/fileadmin/dateien/HMA_joint/00-_About_HMA/03-Working_Groups/EU-IN/2023_02_EU-IN_Involvement_of_competent_authorities_in_externally_funded_projects.pdf**
- Recommendations for **patient engagement** in research:
  - Patient Engagement Resource Centre: **https://patient-engagement.eu/**
  - EUPATI webinar series: **https://toolbox.eupati.eu/webinars/**
  - PARADIGM Patient Engagement Toolbox: **https://imi-paradigm.eu/petoolbox/**
- Helpdesk for **Intellectual Property Rights** issues: **https://www.iprhelpdesk.eu/**
- Information about a **harmonised Data Access Agreement (hDAA)** for sharing and using controlled access data, can be found here (EU-STANDS4PM): **https://www.eu-stands4pm.eu/data_access.html**
- Support for Data reusability: **https://www.eppermed.eu/publications-resources/resources-for-researchers/data-reusability/**
- Support for the development of a **Data Management Plan**:
  - Science Europe:
    - **https://www.scienceeurope.org/media/4brkxxe5/se_rdm_practical_guide_extended_final.pdf**
    - **https://www.scienceeurope.org/media/411km040/se-rdm-template-3-researcher-guidance-for-data-management-plans.docx**
  - Horizon 2020 FAIR Data Management Plan - Annex 1:
    - **http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-data-mgt_en.pdf**
  - The ELIXIR Research Data Management Kit (RDMkit): **https://rdmkit.elixir-europe.org/**
- Supporting documentation on advanced therapies:
  - Scientific recommendations on classification of advanced therapy medicinal products: **https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/advanced-therapies-marketing-authorisation/scientific-recommendations-classification-advanced-therapy-medicinal-products**
  - Development of non-substantially manipulated cell-based advanced therapy medicinal products: flexibility introduced via the application of the risk-based approach: **https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/development-non-substantially-manipulated-cell-based-advanced-therapy-medicinal-products-flexibility-introduced-application-risk-based-approach_en.pdf**
- Supporting documentation on Good Laboratory Practices:

  - OECD Principles of Good Laboratory Practices: **https://www.oecd.org/content/dam/oecd/en/publications/reports/1998/01/oecd-principles-on-good-laboratory-practice_g1gh32e8/9789264078536-en.pdf**
  - OECD series on principles of GLP and compliance monitoring - Management, Characterisation and Use of Test Items **https://www.oecd.org/content/dam/oecd/en/publications/reports/2018/04/management-characterisation-and-use-of-test-items-used-in-glp-studies_3471a5de/da9ee953-en.pdf**
  - OECD Good Laboratory Practice Course (free): **https://www.unido.org/learning-resources/oecd-good-laboratory-practices**
- Supporting documentation on CMC preparedness:
  - Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials: **https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-chemical-and-pharmaceutical-quality-documentation-concerning-investigational-medicinal-products-clinical-trials-revision-2_en.pdf**
  - Registration of Pharmaceuticals for Human Use – Scientific guidelines: **https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/ich-guidelines/ich-guidelines-quality**
  - Target Product Profile: **https://nida.nih.gov/funding/small-business-innovation-research-sbir-technology-transfer-sttr-programs/target-product-profiles**
  - Critical Quality attributes: **https://www.ema.europa.eu/en/documents/presentation/presentation-what-control-cqas-and-cpps-thomas-stangler-behalf-ega_en.pdf**
- Supporting documentation for Investigational Medicinal Product Dossier:
  - CCMO Template IMPD Quality: **https://english.ccmo.nl/documents/2022/05/02/template-impd-quality**
  - CCMO Template IMPD Efficacy and Safety: **https://english.ccmo.nl/documents/2022/05/02/template-impd-efficacy-and-safety**

12 Annex I: List of National Contacts

Name of participating organisation	*Country/Region*	*Regional/National contact*
Austrian Science Fund, (FWF)	Austria	Hannes Zwickl hannes.zwickl@fwf.ac.at Tel.: +43 676 83487 8219 Heike Höller heike.hoeller@fwf.ac.at Tel.: +43 676 83487 8220
The Research Foundation – Flanders, (FWO)	Belgium (Flanders)	Kristien Peeters (SBO) Tel.: +32 (0)2 550 15 95 Toon Monbaliu (FO) Tel.: +32 (0)2 550 15 70 europe@fwo.be
Vlaams Gewest - VLAIO Flanders Innovation & Entrepreneurship, (FIO/VLAIO)	Belgium (Flanders)	Ariane Tiberghien Ariane.Tiberghien@vlaio.be Tel.: +32479291349
Fund for Scientific Research – FNRS, (F.R.S.-FNRS)	Belgium (Wallonia-Brussels Federation)	Maxime Bonsir maxime.bonsir@frs-fnrs.be Tel.: +32 2 504 92 36 Joël Groeneveld Tel.: +32 2 504 92 70 international@frs-fnrs.be
Service Public de Wallonie, (SPW EER)	Belgium (Wallonia)	Vinciane Grimard vinciane.grimard@spw.wallonie.be Tel: +32 (0)81 77 87 18
Canadian Institutes of Health Research, (CIHR)	Canada	Pierre-Luc Coulombe PDD-IGStrategic-CEP-IGStrategique@cihr-irsc.gc.ca
The Ministry of Health of the Czech Republic, (MZCR)	Czech Republic	Monika Kocmanova Monika.kocmanova@azvcr.cz Tel.: +420 778 973 186 Olga Laaksonen Olga.laaksonen@mzd.gov.cz Tel.: +420 604 786 141
Estonia Enterprise, (EIS)	Estonia	Alice Liblik alice.liblik@eis.ee Tel.: +372)6279738 Reet Reinart-Okugbeni reet.reinart@eis.ee Tel.: (+372)56980087
Estonian Research Council, (ETAG)	Estonia	Margit Suuroja Margit.Suuroja@etag.ee Tel.: +372 731 7360 Argo Soon Argo.Soon@etag.ee Tel.: +372 515 3424

Name of participating organisation	*Country/Region*	*Regional/National contact*
Business Finland, (BFRK)	Finland	Norma Saha norma.saha@businessfinland.fi Tel.: +358 50 5577 012 Matti Hiltunen matti.hiltunen@businessfinland.fi Tel: +350 50 5577652
Agence Nationale de la Recherche, (ANR)	France	Mylène Vaillancourt Tel.: (+33) (0) 1 78 09 80 36 Mérick Machouri Tel.: (+33) (0) 1 72 73 06 72 EPPerMed@agencerecherche.fr
Federal Ministry of Research, Technology and Space, (BMFTR) **German Aerospace Center e.V. – Project Management Agency, (DLR)**	Germany	Ute Preuss Alexandra Becker permed@dlr.de Tel.: +49 228 3821 2211
Federal Ministry of Health, (BMG) **German Aerospace Center e.V. – Project Management Agency, (DLR)**	Germany	Fabian Gondorf Joachim Burbiel permed@dlr.de Tel.: +49 228 3821-2211
Saxon State Ministry for Science, Culture and Tourism, (SMWK)	Germany (Saxony)	Gabriele Süptitz gabriele.sueptitz@smwk.sachsen.de Tel.: +49 351 564-64210 Caroline Karapanos caroline.karapanos@smwk.sachsen.de Tel.: +49 351 564-64220
General Secretariat for Research & Innovation, (GSRI)	Greece	Foteini Karagkouni f.karagkouni@gsrt.gr Tel.: +30 213 1300132
National Research, Development and Innovation Office, (NKFIH)	Hungary	Zsuzsanna Kürti ncp@nkfih.gov.hu
Taighde Éireann-Research Ireland, (TE-RI)	Ireland	Suzan Gunbay suzan.gunbay@researchireland.ie
Chief Scientist Office, Ministry of Health, (CSO-MOH)	Israel	Liron Even-Faitelson Liron.ef@moh.gov.il Tel.: +972-2-5082168
National Technological Innovation Authority, (IIA)	Israel	Sarah Chiche sarah.c@innovationisrael.org.il Tel.: +972 3 5118122
Italian Ministry of Health, (IT-MoH)	Italy	Simona Carmen Ursu sc.ursu@sanita.it Alessandra Vittoria Lallo av.lallo@sanita.it

Name of participating organisation	*Country/Region*	*Regional/National contact*
Regione Autonoma Friuli Venezia Giulia, (FVG)	Italy (Friuli-Venezia Giulia)	Ketty Segatti ketty.segatti@regione.fvg.it Tel.: +39 040 3775206 Luciana Grimani Luciana.grimani@regione.fvg.it Tel.: +39 040 3775274
Fondazione Regionale per la Ricerca Biomedica, (FRRB)	Italy (Lombardy)	Giulia Maria Rossignolo giuliamaria.rossignolo@frrb.it bandi@frrb.it Tel.: +39 0267650159
Tuscany Region, (RT)	Italy (Tuscany)	Teresa Vieri Tel..: +39 055 4383289 Monica Malacarne Tel.: +39 0554382334 eppermed@regione.toscana.it
Latvian Council of Science, (LZP)	Latvia	Uldis Berkis Uldis.Berkis@lzp.gov.lv Tel.: +371-29472349
Research Council of Lithuania, (LMT)	Lithuania	Živilė Ruželė zivile.ruzele@lmt.lt Tel.: (+370) 676 14383
National Research Fund, (FNR)	Luxembourg	Gideon Gießelmann gideon.giesselmann@fnr.lu Tel.: +352 691 362 805
The Research Council of Norway, (RCN)	Norway	Karianne Solaas, kso@rcn.no Tel.: +47 945 35 380
National Centre for Research and Development, (NCBR)	Poland	Anna Stępień anna.stepien@ncbr.gov.pl Tel.: +48 22 39 07 210
Fundação para a Ciência e a Tecnologia, (FCT)	Portugal	Rita Cavaleiro Tel.: +351 213 911 541 Pedro Ferreira Tel.: +351 213 924 445 EPPerMed@fct.pt
Vice-Presidency of Azores Regional Government, (VP-GRA)	Portugal (Azores)	Sara de Viveiros Pavão sara.v.pavao@azores.gov.pt Tel.: +351 296 308 903
Executive Agency for Higher Education, Research, Development and Innovation Funding, (UEFISCDI)	Romania	Mihaela Manole mihaela.manole@uefiscdi.ro Nicoleta Dumitrache nicoleta.dumitrache@uefiscdi.ro
Centrum vedecko-technických informácií Slovenskej republiky, (CVTI SR)	Slovak Republic	Maros Halama maros.halama@cvtisr.sk Tel.: +421 917 733 475
National Institute of Health Carlos III, (ISCIII)	Spain	María Adrio Lorente eppermed@isciii.es Tel: +34 918222868

Name of participating organisation	*Country/Region*	*Regional/National contact*
Consejería de Presidencia, Sanidad y Emergencias de la Junta de Andalucía, (CPSEJA)	Spain (Andalusia)	Alicia Milano Curto ep.fps@juntadeandalucia.es
Health Department – Generalitat de Catalunya, (DS-CAT)	Spain (Catalonia)	Carme Pérez peris@gencat.cat Tel.: +34 935566103
Swedish Research Council, (SRC)	Sweden	Abraham Mellkvist-Roos abmr@vr.se Tel.: +46 76 525 7613
Sweden´s Innovation Agency, (VINNOVA)	Sweden	Casper Ullsten-Wahlund casper.ullsten-wahlund@vinnova.se Tel.: +46 8 473 32 06
The Netherlands Organisation for Health Research and Development, (ZonMw)	The Netherlands	Rob Diemel Marcella de Boer Anna Wilbers EP-PerMed@zonmw.nl Tel.: +31 70 349 5252
The Scientific and Technological Research Council of Türkiye, (TÜBİTAK)	Türkiye	N. Selcan TÜRKER selcan.turker@tubitak.gov.tr Tel.: +90 312 298 1760

13 Annex II: Guidelines for Organisations representing Patients or Citizens

DLR, Germany is responsible for administering centrally the financial support for patient organisations or citizen organisations requesting budget from EP PerMed in this call.

For applications including patient organisations or citizen organisations that apply for financial support from EP PerMed, the submission of **annex 6, the patient/citizen involvement plan**, is **mandatory** at every stage to clarify the eligibility of funds.

Funding Organisation	**EP PerMed, budget administered by Deutsches Zentrum fuer Luft- und Raumfahrt e.V., (DLR)**
Country	**Multinational - Financial support to patient organisations or citizen organisations**
Initial funding pre-commitment	1.500.000 €
Regional/National contact for the EP PerMed JTC2027	PerMed@dlr.de
Eligible institutions	Organisations representing patients or citizens only. Definition of eligible organisations: Organisations representing patients or citizens are defined as not-for-profit organisations, which are patient or citizen-focused, and where patients and/or carers and/or family members of patients or representatives of citizens (e.g. communities, populations) represent a majority of members in governing bodies. These are: • Umbrella organisations (e.g. representing either European/international organisations and/or national umbrella organisations for patients or citizens); preferably are independent national partners of these organisations; • European organisations representing patient or citizen communities (i.e. representing national organisations or individual patients or citizens); • National organisations representing patient or citizen communities. **Legitimacy:** the organisation should be formally established and registered as a not-for-profit organisation in one of the EU Member States or Associated Countries.

Additional eligibility criteria	Criteria to be fulfilled by organisations representing patient's or citizen's communities:
	• **Mission/objectives**: the organisation shall have its mission/objectives clearly defined.
	• **Structure**: Includes in its governing structure a designated representative legally authorised to sign a contract with DLR on behalf of EP PerMed.
	• **Accountability**:
	  • With proven activities such as patient/patient family/citizens support and/or advocacy activities and/or health research.
	  • Can demonstrate that its account system is able to trace all costs related to the project and archive these costs for a duration of 5 years after the end of EP PerMed.
	• **Transparency**:
	  • The organisation shall be financially independent, particularly from the private sector (<50% of funding from one or several companies) and disclose to EP PerMed its sources of funding both public and private by providing the name of the bodies and their individual financial contribution, both in absolute terms and in terms of overall percentage of the organisation budget. Any relationship with corporate sponsorship should be clear and transparent. The organisation should publish on its website the registered statutes, sources of funding, and information on their activities.
	To facilitate communication, a contact person shall be identified for each organisation.

Eligible costs	Max. 50.000 € per project (if more than one organisation representing patients or citizens is participating in one consortium the amount should be shared). The **same organisation can max. participate in 3 applications** submitted to the call. Expenses recognised as eligible are: personnel costs and operating expenses (travels, meeting, conference registration, etc.) but excluding office and IT equipment (workstation, mobile phone, tablets, etc.). Staff costs are only eligible, in proportion to the time spent on the project, with justification in the form of a time sheet. Operating expenses must be documented in the accounts. Subcontracting for services (e.g. printing materials) has to be described but is possible in general. Subcontracting between patient organisations within one consortium is not foreseen.

	Expenditure on general, administrative and / or infrastructure costs is eligible respecting the maximum of 50.000 € total budget per project. Overhead costs can be reimbursed up to 25% of direct costs. All justifications and supporting documents are auditable by DLR or by any representative appointed by it during the project and a period of 5 years after the end of EP PerMed (i.e. 5 years after the last payment of balance of EP PerMed by the European Commission).
Funding of public-private partnerships allowed	Yes
Further guidance	For further information, applicants contact **permed@dlr.de**

14 Annex III: Information for applicants concerning regional/national eligibility criteria

Austria

Funding Organisation	**Der Wissenschaftsfonds (FWF)/ Austrian Science Fund** - www.fwf.ac.at
Initial funding pre-commitment	1.500.000 €
Regional/National contact for the EP PerMed JTC2027	Hannes Zwickl, Phone: +43 676 83487 8219, E-mail: hannes.zwickl@fwf.ac.at Heike Höller, Phone: +43 676 83487 8220, E-mail: heike.hoeller@fwf.ac.at
Eligible institutions	The **eligibility criteria** for the Austrian research institution and its appointed principal investigator are described in sections 1.3 and 1.4 of the **FWF Application Guidelines** and the **restrictions on the number of projects**. Austrian research institutions must be registered in the **FWF's Research Institution Portal** before the submission of the pre-proposal. The proposed research must be carried out in Austria under the auspices of the Austrian lead research institution. Applications are submitted by the research institution where the project will be carried out. Please refer to section 1.3.1-1.3.2 of the **FWF Application Guidelines** for more details. Participating Austrian patients' organizations may be financed in the project on a subcontractor basis.
Additional eligibility criteria	In addition to the application to the Call Secretariat, **administrative data must be submitted online to the FWF** on **elane** (**user manual**) for both the pre-proposal and the full proposal stages before each specific deadline. When submitting **pre-proposals** to the FWF, applicants must choose the program category "PIK – International Projects Pre-Proposal" (**deadline 21 January 2027, 2:00 pm CET, local time**) and upload the following documents as individual annexes:

	• CV of the FWF principal investigator (pursuant to the **FWF Application Guidelines**, section 2.2.3, Annex 3). • Proof of publication output of the FWF principal investigator (pursuant to **FWF Application Guidelines**, section 2.2.4). **IMPORTANT:** Please note that applications are only valid once they have been **approved for submission by the research institution (PROFI)** in the submission portal in due time before the specified deadline. For the **full proposal stage**, applicants must choose the program category "KIN– International Projects" (**deadline 26 May 2027, 2:00 pm CEST, local time**). The FWF will contact applicants invited to submit a full proposal with further information.
Eligible costs	The FWF generally does not have any minimum limit. **The maximum limit per project submitted to the FWF is € 450.000. Projects requesting funding above this upper limit will not be eligible.** Project-specific costs are eligible for funding. These include personnel and non-personnel costs that are needed to carry out the project and that are not included in the infrastructure provided by the research institution (see section 2.3 of the **FWF Application Guidelines**). The **FWF does not finance the infrastructure or basic equipment** of research institutions. In addition, funding may be requested for project-specific work at the **associated research partner's institution** (if already registered in the FWF's Research Institution Portal). Associated research partners are researchers working on a project-specific basis at other Austrian research institutions (associated research institutions) and who are making a significant scientific/scholarly contribution to the project. Please refer to section 1.5 of the **FWF Application Guidelines** for more details. The b**udget specified in the national submission must correspond to this consortium partner's budget submitted to the EP** and be calculated on the basis of the applicable FWF personnel cost rates at the time of submission in both the pre-proposal and full proposal stages. Minor deviations resulting from updated FWF personnel cost rates between stages are permissible. To ensure consistency, project costs should be calculated on **elane** (FWF)

	prior to inclusion in the consortium proposal. The FWF does not fund institutional or indirect overhead costs. The "**General Project Costs**" automatically calculated in the **elane** cost breakdown on the basis of the requested FWF cost categories are an FWF-specific flat rate and may be reported under the "Overheads" heading in the EP budget forms for technical reasons, even though they do not constitute overheads in the FWF sense.
Funding of public-private partnerships allowed	Yes
Further guidance	

Belgium (Flanders, FWO)

Funding Organisation	**The Research Foundation – Flanders, (FWO)**
Initial funding pre-commitment	
Regional/National contact for the EP PerMed JTC2027	
Eligible institutions	
Additional eligibility criteria	
Eligible costs	
Funding of public-private partnerships allowed	
Further guidance	

Belgium (Flanders, FIO/VLAIO)

Funding Organisation	**Fonds Innoveren en Ondernemen, (FIO/VLAIO)**
Initial funding pre-commitment	1.000.000 €
Regional/National contact for the EP PerMed JTC2027	Ariane Tiberghien; +32479291349; Ariane.Tiberghien@vlaio.be
Eligible institutions	Universities and research institutes as subcontractors of industry partners.
Additional eligibility criteria	Submission of the Flemish addendum via the E-tool of VLAIO latest simultaneously with the international deadline. Please contact Ariane Tiberghien in advance.
Eligible costs	Staffing costs, overhead costs, operating costs, third party services, investment costs Extended eligibility check Knowledge Hub costs need to be embedded in the project budget and are subject to VLAIO regulations.
Funding of public-private partnerships allowed	Yes
Further guidance	Template annex internationale en interregionale projecten **https://www.vlaio.be/nl/subsidies-financiering/onderzoeksproject/aanvraagprocedure-voor-de-subsidie-onderzoeksproject** - Template begroting-saanvraag (same web-page) *1: Main applicant must be a company. Academic partner can only participate as research partner of the company. *2: Sufficient valorisation potential is a requirement

Belgium (Wallonia-Brussels Federation)

Funding Organisation	**Fund for Scientific Research – FNRS, (F.R.S.-FNRS)**
Initial funding pre-commitment	300.000 €
Regional/National contact for the EP PerMed JTC2027	Maxime Bonsir, Tel.: +32 2 504 92 36, maxime.bonsir@frs-fnrs.be Joël Groeneveld, Tel.: +32 2 504 92 70, international@frs-fnrs.be
Eligible institutions	All eligibility rules and criteria can be found in the **PINT-MULTI regulations**.
Additional eligibility criteria	All eligibility rules and criteria can be found in the **PINT-MULTI regulations**.
Eligible costs	For "overhead" costs: - Operating expenses: up to 1% within the granted budget. This percentage should be included in the requested operating budget. - Personnel: up to 2% outside of the granted budget. This percentage will be paid upon reimbursement of expenses to institutions by the F.R.S.-FNRS. If the project involves the recruitment of a PhD student, the project duration of the F.R.S.-FNRS sub-project could be up to four years (see **PINT-MULTI Regulations** for details) Please check the **Practical guide on costs** for any other questions.
Funding of public-private partnerships allowed	Yes

	Please note that the F.R.S.-FNRS only funds Basic research (low Technology Readiness Level) carried out in a Research institution from the "Fédération Wallonie-Bruxelles". The F.R.S.-FNRS will not fund industrial partners or any activity related to the private sector. Nevertheless, partners funded by the F.R.S. -FNRS can be in a consortium where there are also partners from the private sector. Clinical research is eligible for funding by the F.R.S.-FNRS under the condition that the funded research is oriented towards the understanding of fundamental mechanisms, excluding clinical trials with purely therapeutic or industrial goals.
Further guidance	Applicants to F.R.S.-FNRS funding must provide basic administrative data by submitting an administrative application on **e-space within 5 working days after the general deadline of EP PerMed to be eligible**. Please select the "PINT-MULTI" funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS.

Belgium (Wallonia)

Funding Organisation	**Service Public de Wallonie, (SPW EER)** - https://recherche.wallonie.be/eppermed
Initial funding pre-commitment	1.000.000 €
Regional/National contact for the EP PerMed JTC2027	Vinciane Grimard - +32 (0)81 77 87 18 – vinciane.grimard@spw.wallonie.be
Eligible institutions	Companies, Universities, research centers
Additional eligibility criteria	- **Regional submission to be done in parallel to the main submission via the** regional submission platform**.** - At least one Walloon company in the consortium - At least 40% of the budget of Walloon entities for the company(ies) - Regional partners are in order administratively for any other projects funded by Wallonia - Projects must be aligned with the Walloon R&I strategy and the project must have a positive impact on Walloon economy - Projects must start at least at TRL3 - Partners must demonstrate their capacity to perform the tasks they are assigned in the project and to exploit the results
Eligible costs	**Guide des dépenses éligibles**
Funding of public-private partnerships allowed	Yes
Further guidance	**https://recherche.wallonie.be/eppermed**

Canada

Funding Organisation	**Canadian Institutes of Health Research (CIHR)**
Initial funding pre-commitment	840.645 € (1.350.000 CAD)
Regional/National contact for the EP PerMed JTC2027	Pierre-Luc Coulombe PDD-IGStrategic-CEP-IGStrategique@cihr-irsc.gc.ca
Eligible institutions	Refer to the list of CIHR **Eligible Institutions** Authorized to Administer Grant and Award Funds
Additional eligibility criteria	For an application to be eligible, all the requirements stated below must be met: 1. The Nominated Principal Applicant (NPA) leading the Canadian component of the consortium must be an **independent researcher** affiliated with a Canadian postsecondary institution and/or its affiliated institutions (including hospitals, research institutes and other non-profit organizations with a mandate for health research and/or knowledge translation). 2. The NPA must have their **substantive role in Canada** for the duration of the requested grant term. 3. The Institution Paid for the Canadian-led application must be **authorized to administer CIHR funds** by the application deadline (see **List of CIHR Eligible Institutions**). 4. If the Canadian team in the consortium includes more than one Canadian researcher, only one of them must be named the NPA on the Pre-Proposal and Full Proposal. The additional Canadian researchers must be listed as "Other personnel participating in the project" under this NPA in the EP PerMed application. 5. CIHR will follow the **Early Career Researcher definition** as outlined in the EP PerMed 2027 Section 16 (Annex III).

	6. An individual cannot submit more than one application as an NPA. If the NPA submits more than one application, CIHR will automatically withdraw the last application(s) submitted based on the timestamp of submission. Maximum amount per grant is $150,000CAD/year for 3 years. Canadian consortium members invited to submit a Full Proposal to EP PerMed must also complete an abbreviated CIHR application (in one of the two official languages of Canada) and submit it using **ResearchNet** by May 25, 2027, 8:00 p.m. ET.
Eligible costs	Applicants are advised to consult the **Use of Grant Funds** section of the Tri-Agency (CIHR, NSERC and SSHRC) Guide on Financial Administration (TAGFA) to determine if an expenditure is an appropriate use of grant funds. Conditions of Funding: In addition to the **general conditions of funding** governing CIHR **grants**, the following are the program-specific conditions of funding applicable to this funding opportunity: • Data related to First Nations, Inuit or Métis communities whose traditional and ancestral territories are in Canada must be managed in accordance with data management principles developed and approved by those communities, and on the basis of free, prior and informed consent. This includes, but is not limited to, considerations of Indigenous data sovereignty, as well as data collection, ownership, protection, use, and sharing. • CIHR is a signatory to the World Health Organization's **Joint Statement on Public Disclosure of Results from Clinical Trials** ("WHO Joint Statement") requiring all clinical trials to be registered and the results disclosed publicly in a timely manner. For more information, please consult the **CIHR Policy Guide - Requirements for Registration and Disclosure of Results from Clinical Trials.**

	• CIHR reserves the right to terminate or suspend funding if there is a determination of unacceptable national security risk by the Government of Canada. • It is incumbent upon the Canadian researchers to review and understand all expectations outlined in **EP PerMed** Guidelines, including the requirement for a Consortium Agreement*. • To complete the **ResearchNet** application for funding, you must include your personal information. CIHR will collect, use, retain and dispose of your personal information in accordance with the Access to Information and Privacy Act. If applicable, the information provided may be shared, in whole or in part, with CIHR Institute Staff. CIHR will not share the information collected through your applications in CIHR **ResearchNet** with other institutions or signatories to EP PerMed. • Funding applications submitted to EP PerMed will be held in jurisdictions outside of Canada and will not be subject to the provisions of the Privacy Act. Information submitted to EP PerMed as part of the applications will be governed by the provisions of EU data protection laws, the European Data Protection Regulation (GDPR). Please note that all parties on applications must also comply with (GDPR) (2016/679). • The Nominated Principal Applicant (NPA) is responsible for the following reporting requirements: ○ An electronic Final Report. This online report will be made available to the NPA on **ResearchNet** at the beginning of the grant funding period and can be filled in as the research progresses. **It is noted that CIHR does not retain or claim any rights to IP in relation to research that it funds. Accordingly, the Canadian researchers retain full freedom in negotiating the Consortium Agreement required, including whether or not to accept the IP conditions.*
Funding of public-private partnerships allowed	Yes, however the CIHR funds must be administered through the CIHR authorized administering institution (Institution Paid). Access to the funds will depend on the organization's role on the project and may require agreements with the Institution Paid. In some cases, partners may be required to secure their own funding.
Further guidance	

Czech Republic

Funding Organisation	**The Ministry of Health of the Czech Republic (MZCR)**
Initial funding pre-commitment	500.000 €
Regional/National contact for the EP PerMed JTC2027	**Monika Kocmanova**; National coordinator on Health-related European Partnerships (AZVCR); Email: moni-ka.kocmanova@azvcr.cz; Phone: + 420 778 973 186; **Olga Laaksonen**; Head of the Science, Research, and Subsidies for Education Unit (MZCR); Email: olga.laaksonen@mzd.gov.cz; Phone: +420 604 786 141
Eligible institutions	**Research Organisations, Enterprises, Patient Organisations.** All eligibility rules and criteria can be found on the Czech Health Research website (**PerMed Výzva 2027 – AZV ČR**). It is **strongly recommended** to contact the responsible person at the Czech Health Research Council (prior to submission regarding the eligibility criteria). • **Conditions for PO funding** – Patients organisations can receive direct funding if they take an active role in the project´s research activities. This means they must contribute to specific research objectives (for example, by being involved in one or more work packages) and these types of research activities must be clearly described in their **status**. • **Definition of ECR** - A natural person engaged in research who, in the year of submission of the Project proposal to the call for proposals, has received their Ph.D. academic title or its equivalent in the past 8 years, or has obtained it no later than the date of conclusion of the Contract/issuance of the Project Decision. If the Proposer has been on maternity or parental leave, has suffered a long-term illness, or has interrupted his/her scientific career for similar objective reasons, the time limit of 8 years from the award of the academic degree of Ph.D. or its equivalent is increased by this period. These facts (award of the degree, parental leave, etc.) shall be documented by the Applicant by means of a Sworn Statement.

Additional eligibility criteria	**Eligibility criteria for the Principal Investigator:** The PI must hold a Ph.D. degree (for more information, please refer to the national document "Podmínky pro zapojení českého uchazeče do výzvy", available on the AZV CR website). MZCR/AZVCR sets a criterion for the **maximum workload, which must not exceed 1.00 FTE within a single submitted project.** There is **no minimum workload requirement for the PI** in relation to European Partnerships (EP) in health-care area imposed by the national funding authority (MZCR). However, the allocated FTE must correspond to the actual workload required for the project. Within the EP, the assigned FTE is subject to verification by the institution or organisation employing the PI. Therefore, the provisions of Act No. 262/2006 Coll., the Labour Code, must be respected. AZV CR does not impose any additional FTE-related restrictions within the framework of the EP. **Eligible experimental approaches and disciplines:** The Ministry of Health of the Czech Republic (MZCR) is not permitted to finance projects focused exclusively on basic research. It may, however, support projects that combine basic and applied research, provided that applied research plays the principal role. **Submission of the proposal (or other information) at the national level:** **Prior to submission of the pre-proposal** to EP PerMed, Czech researchers need to submit to the Czech Health Research Council the following documents: 1. **Sworn Statement of a Legal Entity / Natural Person (mandatory)** 2. **Sworn Statement for a Research Organisation** (if relevant) 3. **Sworn Statement of composition consortium** (only if SMEs or industry are involved in the project proposal from the Czech side) 4. **Application Form** Czech partners are required to complete a **national Application Form**, providing basic information about the applicant and any co-applicant(s), if applicable, including their respective budgets. It is necessary to list all national institutions involved in the project due to funding requirements. All these documents are available on the website at the Czech Health Research Council: PerMed Výzva 2027 – AZV ČR.

	Prior to submission of the full proposal to EP PerMed, Czech researchers need to submit to the Czech Health Research Council the following documents: 1. **Documents** related to **professional competence**, depending on the nature of the project, must be provided in the form of a Sworn Statement, which will be available on the website at the Czech Health Research Council AZV ČR – PerMed Výzva 2027 – AZV ČR. 2. **Updated Application Form** Czech partners are required to complete the **updated national Application Form**, providing basic information about the applicant and any co-applicant(s), if applicable, including their respective budgets. It is necessary to list all national institutions involved in the project due to funding requirements. According to Czech regulations, the main Czech applicant will sign a grant agreement with the national funding authority (MZCR) and, if there are any other Czech co-applicant(s), will subsequently enter into a cooperation agreement with them. At the international level (pre- or full proposal), it is preferable to list only one Czech partner – the main applicant. If needed, it is possible to list more than one partner (in accordance with the call rules); however, at the national level, there will be one main Czech applicant while the remaining national institutions will act as co-applicants. Together, they must share the allocated project budget among themselves. The total project budget must not exceed **EUR 250,000.** In case the projects of Czech participants are recommended for funding based on the results of the international evaluation and after the approval of the representatives of the funding authorities of the countries participating in the EP PerMed calls, the Ministry of Health of the Czech Republic / the Czech Health Research Council may ask the successful Czech participants to submit additional documents in order to issue a decision on the provision of purpose-special support according to the rules established by the Ministry of Health of the Czech Republic / Czech Health Research Council.
Eligible costs	All eligibility of costs, types and their caps can be found on the Czech Health Research Council (**PerMed Výzva 2027 – AZV ČR).** It is **recommended** to contact the responsible person at the Czech Health Research Council (prior to submission regard-ing the eligibility criteria).

Funding of public-private partnerships allowed	Yes
Further guidance	**PerMed Výzva 2027 – AZV ČR** **IMPORTANT:** All projects will be funded under the Programme for the Support of Applied Health Research for the Years 2024–2030 and **must therefore start on 1 January 2028 and be completed no later than 31 December 2030**, as the programme itself ends at the end of that year. **In the Consortium Agreement, it must therefore be stated that due to the national funding conditions applicable to the Czech partner, the project duration for the Czech partner differs from that of the other consortium partners. The Czech partner must start its project activities on 1 January 2028 and complete them no later than 31 December 2030, without any extension possible.** **Please note:** the Call is administered by the Czech Health Research Council (AZV CR) at the national level but the Ministry of Health of the Czech Republic (MZ CR) is the funding organisation.

Estonia (EIS)

Funding Organisation	**Estonian Business and Innovation Agency (EIS)** - www.eis.ee
Initial funding pre-commitment	500.000 €
Regional/National contact for the EP PerMed JTC2027	Alice Liblik, (+372)6279738, alice.liblik@eis.ee Reet Reinart-Okugbeni, (+372)56980087, reet.reinart@eis.ee
Eligible institutions	For-profit organisations are eligible; The eligibility of applicants and costs, as well as complementary administrative requirements are subjected to the Estonian national regulation, link: **Ettevõtjate teadus- ja arendustegevuse ning innovatsioonialase rahvusvahelise koostöö toetamine-Riigi Teataja**
Additional eligibility criteria	Official landing page for JTC2027 call for Estonian companies will be published soon on **www.eis.ee**, and it will include all the relevant links to national legislation regulating the funding of Estonian enterprises. **National criteria** To receive EIS funding, a company that has received a positive decision must meet the following conditions: • The company is an enterprise registered in Estonia • The company is not an undertaking in difficulty • The company has the necessary resources to cover the self-financing of the project • The company has a significant impact on the Estonian economy • The following components are generally considered in terms of impact on the Estonian economy: - Location of jobs - Location of production - Location of development activities - Location of IO

	- Location of sales revenue • In addition, we look at the overall picture, how the company's economic activities and the added value generated by them are related to Estonia. **Additional steps for applications from Estonia** Applicants from Estonia are required to contact Enterprise Estonia for advice before submitting a proposal to the EP PerMed call. Initial contact should be made via the Enterprise Estonia website (link to the JTC2027 landing page will be added soon). Estonian participants must also submit a funding application to Enterprise Estonia when you receive a positive evaluation and funding availability letter. You must justify your financial situation and strategic position with supporting documents.
Eligible costs	Eligible costs are costs connected to R&D activities such as salaries (the salary of employees working in Estonia related to the project development work is supported), materials, services, travel costs, renting of and depreciation of equipment during the project period, costs of acquiring, validating and protecting patents and other tangible assets. Examples of non-eligible costs: sales, marketing, business administration, general administration, bookkeeping, VAT, costs of validating and protecting trademark acquisition. For more information on eligibility of costs, contact the call contact person Alice Liblik / Reet Reinart-Okugbeni. **Ettevõtjate teadus- ja arendustegevuse ning innovatsioonialase rahvusvahelise koostöö toetamine-Riigi Teataja**
Funding of public-private partnerships allowed	Yes – public institutions, e.g. Academic research institutions are funded through Estonian research Agency ETAG – contact Estonian Research Council guidelines for eligibility criteria applicable to public institutions.
Further guidance	JTC2027 call landing page for Estonian companies will soon be published at **www.eis.ee**

Estonia (ETAG)

Funding Organisation	**Estonian Research Council, (ETAG)**
Initial funding pre-commitment	300.000 € max. 150.000 € as a project partner and max. 300.000 € as a project coordinator.
Regional/National contact for the EP PerMed JTC2027	Margit Suuroja Margit.Suuroja@etag.ee Tel.: +372 731 7360 Argo Soon Argo.soon@etag.ee Tel.: +372 515 3424
Eligible institutions	The Host Institution must be legal entity registered and located in Estonia and has an Estonian bank account. The Host Institution can't be a company within the meaning of the Commercial Code.
Additional eligibility criteria	The Principal Investigator: 1. must have an updated public profile in the Estonian Research Information System (ETIS) by the submission deadline (in case of two-stage application, by the preproposal deadline); 2. must hold a doctoral degree or an equivalent qualification. The degree must be awarded by the submission deadline (in case of two-stage application, by the preproposal deadline) at the latest; 3. must have published at least three articles that comply with the requirements of Clause 1.1 of the ETIS classification of publications, or at least five articles that comply with the requirements of Clauses 1.1, 1.2, 2.1 or 3.1, within the last five calendar years prior to the preproposal deadline. If the Principal Investigator has received the PhD degree outside Estonia, its correspondence to an Estonian doctoral degree must be recognised by either the Estonian ENIC-NARIC Centre or the Host Institution in accordance

	with the Regulation of the Government of the Republic of April 6, 2006, No. 89 "Evaluation and academic recognition of documents proving foreign education and the name of the qualification awarded in the foreign education system terms and conditions of use". The Funding Organisation may ask for a relevant Evaluation Report. If several Estonian institutions participate in a proposal, all institutions must have a Principal Investigator who meets the national eligibility requirements.
Eligible costs	1. Personnel costs are monthly salaries (along with all state taxes, contributions, and compensations arising from law) of the project participants, calculated according to their commitment and in proportion to their total workload at their Host Institution. 2. Other direct costs are: - travel costs that may cover expenses for transport, accommodation, daily allowances and travel Insurance - consumables and minor equipment directly and fully related to the project; - publication and dissemination of project results; - organising meetings, seminars or conferences (e.g room rent, catering, equipment rental and related costs); - fees for participating in scientific forums, conferences and other events directly and fully related to the project; - patent costs; - all other costs that are identifiable as clearly required for carrying out the project (e.g. translation, copy editing, webpage hosting, postage costs etc.) and are directly and fully related to the project. 3. Indirect costs (overhead) are costs that cannot be identified as specific costs directly linked to the performance of the action and/or should cover the general expenses of the Host Institution related to the management of the grant. Office consumables and costs for equipment and services intended for general use (e.g., phone bills, copy service, printer) should be covered from the indirect costs. Indirect costs are 15% of the personnel costs of the Estonian sub-project. 4. Subcontracting costs are direct costs. Subcontracting costs should cover only additional or complementary research-related tasks (e.g. analyses, conducting surveys, building a prototype, etc.) performed by third

	parties. Subcontracting costs should not be included in the overhead calculation. The activities and budget should be described in the proposal. Core project tasks should not be subcontracted. Subcontracting costs may not exceed 15% of the total costs of the Estonian sub-project. 5. Double funding of activities is not acceptable (i.e. the same cost item may not be reimbursed from different funding sources) 6. If several Estonian institutions participate in one proposal, the sum of their requested budgets may not exceed the maximum contribution per proposal of the respective national Funding Organisation indicated in the call documents.
Funding of public-private partnerships allowed	Yes
Further guidance	**https://etag.ee/wp-content/uploads/2026/04/Vastavusnouded-RV-uhiskonkurssidel_-EN_marts2026-2.pdf**

Finland

Funding Organisation	**Innovaatiorahoituskeskus Business Finland, (BFRK)** - **https://www.businessfinland.fi/en/**
Initial funding pre-commitment	3.000.000 €
Regional/National contact for the EP PerMed JTC2027	Norma Saha: **norma.saha@businessfinland.fi**; +358 50 5577012 Matti Hiltunen: **matti.hiltunen@businessfinland.fi**; +350 50 5577652
Eligible institutions	Academic Partners, private for-profit partners, wellbeing services counties or HUS (and the project is implemented at a university hospital). Up to date funding conditions can be found from Business Finland's web service: **https://www.businessfinland.fi/en/for-finnish-customers/services/funding**and call text (once available). The call specific requirements/exceptions will be provided in the call text.
Additional eligibility criteria	No limitations regarding the scope of the call.
Eligible costs	Funding terms and conditions .
Funding of public-private partnerships allowed	Yes
Further guidance	Funding is intended to companies', research organisations' and wellbeing service counties' (incl. HUS) R&D projects, including joint ones between them, which fulfil both the EPPerMed and Business Finland criteria.

France

Funding Organisation	**Agence Nationale de la Recherche, (ANR) –** https://anr.fr/
Initial funding pre-commitment	2.500.000 € Anticipated number of funded research groups: ~7-9
Regional/National contact for the EP PerMed JTC2027	Mylène Vaillancourt, +33 1 78 09 80 36 Mérick Machouri, +33 1 72 73 06 72 EPPerMed@anr.fr
Eligible institutions	Eligible institutions: ANR may fund research organisations and undertakings, as defined by the EC regulation on State aid for research, development and innovation (see the ANR funding regulations for further reference). As for research organisations, only those that have their primary establishment in France may be funded. As for undertakings, those that have their real head office in an EU member State and having an establishment (primary or secondary) in France may be funded. Within this framework, public research institutions (such as EPST, EPIC, Universities, University hospitals) as well as foundations can apply, in general for up to 100% of direct costs. This list is not comprehensive and funding rates vary. Enterprises may also be eligible. Funding rates vary based on the types of research and types of enterprises. For more information, please refer to the ANR **Financial Regulations ("at actual costs" version)**. Please note that companies in difficulty cannot receive ANR subventions. Please consult **https://anr.fr/fr/rf/** for full details. Private partners are asked to indicate their SIRET number in the pre- and full-proposal template (partner description: "Project Consortium", "Other information").

Additional eligibility criteria	At the **full proposal stage, partners requesting funding from ANR will be asked to follow a parallel submission procedure on the ANR submission platform: https://iris.anr.fr/fr/login** ANR does not allow double applications nor provide double funding to finance projects or part of projects that have been funded through other national and international calls. ANR will cross-check the proposals submitted to ensure they have not been submitted to the ANR through other calls. Partners, whether legal entities or natural persons, who are subject to sanction(s) imposed by the institutions of the European Union are excluded from this call. The ANR will declare ineligible any Partners requesting funding from the Agency who are, within the submitted project, associated with Partners subject to a sanction measure. As of the publication date, these exclusions concern in particular Partners from the following countries: Russia and Belarus; as well as Partners located in Ukrainian territories not under the control of the Ukrainian government. This list is not exhaustive and may evolve should new sanctions be adopted by the European Union. In keeping with the national PPST policy (Protection of the scientific and technologic potential of France) applicants to ANR should consult their local "FSD" (security and defence officer, where available) on their project before applying. Applications to ANR may be forwarded to the HFSD of the French Ministry of research and higher education for screening. A negative appraisal by the HFSD may cause ANR to reject the proposal.
Eligible costs	Eligible costs and rates of funding depend on the type of partners. Among others, eligible costs may include the following: personnel costs; equipment costs; consumables and animal costs; travel and subsistence costs; sub-contracting costs, if necessary, to carry out the proposed activities (sub-contracting costs max. 50% of requested budget per partner). For public research organisations, only personnel costs of fixed-term contracts are eligible (except for an EPIC in partnership with an enterprise). The ANR heading for "overheads" in the ANR financial regulations is "frais d'environnement". 13,5% of the total eligible costs must be applied for if the partner is a public research organisation (or other organisation funded at "marginal" costs), or up to 68% of the total personnel costs and up to 7% of other costs for partners funded at full economic cost (such as enterprises). Please refer to ANR's financial regulations ("Règlement financier relatif aux modalités d'attribution des *aides à coûts réels*" : **https://anr.fr/fr/rf/**) for full details.

	ANR has a maximum funding per partner for this call: a research team can be funded with a maximum amount of 330 000 € for a coordinating partner and 280 000 € for a simple partner. There is a minimum amount per partner: 15 000 €.
Funding of public-private partnerships allowed	Yes
Further guidance	Plan d'Action 2027 : **https://anr.fr/fr/pa2027/** Règlement financier relatif aux modalités d'attribution des *aides à coûts réels* : **https://anr.fr/fr/rf/** ACCESS TO GENETIC RESOURCES AND BENEFIT-SHARING: Funded teams participating in projects falling within the scope of the regulations on access to genetic resources and benefit-sharing will be required to provide evidence to demonstrate compliance with these obligations and must ensure that all data relating to such genetic resources or associated traditional knowledge are kept in order to demonstrate that the necessary due diligence has been exercised. In case of a conflict of interpretation between the terms and conditions stated in this annex and the "*Modalités de participation*" and "*Règlement financier relatif aux modalités d'attribution des aides à coûts réels*", the latter shall prevail.

Germany (BMFTR)

Funding Organisation	**Federal Ministry of Research, Technology and Space (BMFTR)** **https://www.gesundheitsforschung-bmftr.de/**
Initial funding pre-commitment	3.000.000 € in total. Anticipated number of funded research groups: ≈10
Regional/National contact for the EP PerMed JTC2027	Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR) – DLR Projektträger (DLR-PT for BMFTR) Division Health Heinrich-Konen-Straße 1 53227 Bonn, Germany Dr. Ute Preuss and Dr. Alexandra Becker +49 (0) 228 3821 2211 **PerMed@dlr.de**
Eligible institutions	Legal bodies: • Universities (incl. university hospitals) • Clinical and public health institutions • Non-university research institutions • Commercial enterprises and industry Note: Commercial enterprises and industry are funded according to the AGVO for research and development projects. Patient organisations are not eligible to apply for BMFTR funding in the JTC2027.
Additional eligibility criteria	**New in JTC2027: Within one consortium only one German national funder can be asked for funding, either BMFTR or BMG.** **The maximum amount of budget that can be requested from BMFTR within one consortium is 300.000 € (including "Projektpauschale" if applicable). If two partners would like to request BMFTR funding within one consortium the combined requested budgets must not exceed 300.000 €.**

	For BMFTR applicants, the number of applications per principal investigator from academia or research institutions and from the clinical/public health sector is limited to one. For applicants from industry (including SMEs) the number of applications is limited to one per organisation. Please note that country specific requirements might apply to this call. For further information follow the links below or contact the national representative. See also the German version of the call published on **https://www.gesundheitsforschung-bmftr.de/de/20036.php** .
Eligible costs	Personnel Consumables Subcontracts Equipment Travel Other costs Overheads ("Gemeinkosten" - applicable e.g. for Helmholtz-Centres and Fraunhofer-Society - as well as "Projektpauschale" - applicable for universities and university hospitals.)
Funding of public-private partnerships allowed	Yes
Further guidance	For further information on the "Projektpauschale" please refer to "BMFTR Formularschrank": **https://foerderportal.bund.de/easy/easy_index.php?auswahl=easy_formulare&formularschrank=bmbf#t1**

Germany (BMG)

Funding Organisation	**Federal Ministry of Health, Germany (BMG) /** **German Aerospace Center e.V. – Project Management Agency, (DLR)**
Initial funding pre-commitment	2.000.000 € Anticipated number of funded research groups: ≈6-8
Regional/National contact for the EP PerMed JTC2027	Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR) – DLR Projektträger (DLR-PT for BMG) Division Health Heinrich-Konen-Straße 1 53227 Bonn, Germany Dr. Fabian Gondorf Dr. Joachim Burbiel +49 (0) 228 3821 2211 PerMed@dlr.de
Eligible institutions	Legal bodies: • Universities (incl. university hospitals) • Clinical and public health institutions • Non-university research institutions • Commercial enterprises and industry Note: Commercial enterprises and industry are funded according to the AGVO / GBER (General Block Exemption Regulation for research and development projects.
Additional eligibility criteria	**New in JTC2027: Within one consortium only one German national funder can be asked for funding, either BMFTR or BMG. The maximum amount of budget that can be requested from BMG within one consortium is 300.000 €. If two partners would like to request BMG funding within one consortium the combined requested budgets must not exceed 300.000 €.**

	For BMG applicants the number of applications per principal investigator from academia or research institutions and from the clinical/public health sector is limited to one. For applicants from industry (including SMEs), the number of applications is limited to one per organisation. Please note that country specific requirements might apply to this call. For further information follow the links below or contact the national representative.
Eligible costs	Personnel Consumables Subcontracts Equipment Travel Other costs
Funding of public-private partnerships allowed	Yes
Further guidance	

Germany (Saxony)

Funding Organisation	**Saxon State Ministry for Science, Culture and Tourism (SMWK) -** https://www.smwk.sachsen.de/
Initial funding pre-commitment	1.000.000 €
Regional/National contact for the EP PerMed JTC2027	Gabriele Süptitz gabriele.sueptitz@smwk.sachsen.de +49 351 564 – 64210 Caroline Karapanos Caroline.karapanos@smwk.sachsen.de +49 351 564 - 64220
Eligible institutions	Saxon universities and research institutions are eligible for funding (see RL EuProNet (**https://www.revosax.sachsen.de/vorschrift/17180-RL-EuProNet**)
Additional eligibility criteria	No additional eligibility criteria.
Eligible costs	See Saxon funding guideline RL EuProNet (**https://www.revosax.sachsen.de/vorschrift/17180-RL-EuProNet**)
Funding of public-private partnerships allowed	Yes
Further guidance	See RL EuProNet (**https://www.revosax.sachsen.de/vorschrift/17180-RL-EuProNet**)

Greece

Funding Organisation	**General Secretariat for Research & innovation, (GSRI) / Ministry of Development**
Initial funding pre-commitment	
Regional/National contact for the EP PerMed JTC2027	
Eligible institutions	
Additional eligibility criteria	
Eligible costs	
Funding of public-private partnerships allowed	
Further guidance	

Hungary

Funding Organisation	**National Research, Development and Innovation Office, (NKFIH)**
Initial funding pre-commitment	500.000 € (Max. 300,000 € / Hungarian partner)
Regional/National contact for the EP PerMed JTC2027	Zsuzsanna Kürti ncp@nkfih.gov.hu
Eligible institutions	Institution of higher education, Other budgetary research institution, Other budgetary institution (outside education or research), Enterprise-based research organisation, Enterprise (non-research type), Non-profit research organisation, Other non-profit organisation (outside research), HUN-REN Hungarian Research Network. All eligibility rules and criteria can be found in the national call. **Please consult the national call for participation eligibility and funding intensity: Call for proposals to support Hungarian organisations successfully participating in the joint international calls for proposals of European Partnerships in Horizon**: https://nkfih.gov.hu/palyazoknak/nkfi-alap/horizont-europa-europai-partnersegek-magyar-szervezetek-tamogatasa-2024-121-he-partnerseg/palyazati-felhivas Applicants are advised to verify the applicable funding intensity and eligibility conditions in the relevant National Call.
Additional eligibility criteria	We ask all Hungarian applicants to consult the Hungarian national call for information on eligibility.
Eligible costs	Personnel (temporary, permanent), subcontracting, services, travel, consumables, equipment, coordination, communication and dissemination, overhead (20%), overhead for travel related activities (5%). Please consult the national call for cost eligibility.

	https://nkfih.gov.hu/palyazoknak/nkfi-alap/horizont-europa-europai-partnersegek-magyar-szervezetek-tamogatasa-2024-121-he-partnerseg/palyazati-felhivas
Funding of public-private partnerships allowed	Yes
Further guidance	The Hungarian partners of proposals recommended for funding have to submit an application for the national call after having been informed of the international funding decision. For details, please refer to the Guide for Applicants for the 2024-1.2.1-HE_PARTNERSÉG national call : **https://nkfih.gov.hu/palyazoknak/nkfi-alap/horizont-europa-europai-partnersegek-magyar-szervezetek-tamogatasa-2024-121-he-partnerseg/palyazati-felhivas**

Ireland

Funding Organisation	**Taighde Éireann-Research Ireland, (TE-RI)**
Initial funding pre-commitment	650.000 €
Regional/National contact for the EP PerMed JTC2027	Suzan Gunbay, EU Programmes Officer suzan.gunbay@researchireland.ie
Eligible institutions	Irish Host Research bodies eligible for Research Ireland funding. Please refer to Research Ireland's Policies and Guidance for the list of eligible Research Performing Organisations: **Eligibility Information**
Additional eligibility criteria	**Only an academic partner or coordinator based in an eligible Irish Host Research body may apply for Research Ireland funding.** The Irish-based applicant must: • hold a PhD or equivalent qualification for at least 3 years by the pre-proposal deadline. The official date is defined as the day, month and year that the degree was conferred i.e., the month and year printed on the official PhD certificate. **AND** • be a member of the academic staff of an eligible Research Body (permanent or with an active contract that covers the period of the grant) **OR** • be a contract researcher with a contract that covers the period of the grant, who is recognised by the eligible Research Body as an independent investigator and will have an independent office and research space for which he/she will be fully responsible for at least the duration of the Research Ireland grant.

	OR • be an individual who will be recognised by the eligible Research Body upon receipt of the grant as an academic staff or as a contract researcher as defined above. The applicant does not necessarily need to be employed by the Research Body at the time of the application submission. **AND** • be an author on at least three international peer-reviewed articles. Only original research publications, and not review articles or other secondary research literature, are acceptable. Please refer to the Research Ireland call webpage for more information on eligibility criteria. Please note that Research Ireland may contact applicants directly to confirm eligibility post submission. **Clinical trials** Please note **clinical trials and investigations are not eligible for funding by Research Ireland for the Irish-based applicant**. Where clinical studies are proposed within the workplan of a proposal, study sites and the delineation of activities among proposal partners should be made clear.
Eligible costs	All requested costs must be comprehensively justified. Please include detailed descriptions and cost itemisation in the proposal. Funding is provided for up to 100% of eligible costs. The following indicates the maximum levels of funding that may be requested: Up to €330,000 direct costs per project for Irish-based researchers applying as a project partner Up to €405,000 direct costs per project for Irish-based researchers applying as a project coordinator The maximum total award, including 30% overhead contribution, will be up to €430,000, for a partner and up to €530,000 for applicants who take on the role of coordinator. **Eligible costs**

	1. **Salary-related costs** for research personnel. Please use current **Research Ireland Team Member Salary Scales**. The Irish partner cannot request their own salary or buy-out. 2. **Small equipment costs** up to a maximum value of €10K 3. **Travel costs** with consideration for Research Ireland's **Guidance for Sustainable Travel Policy** 4. **Direct running costs** (materials and consumables) **5. Dissemination and knowledge exchange costs** 6. **Subcontracting costs** are considered an eligible budget category however strong justification for subcontracting must be provided and pre-approved directly with Research Ireland in advance of proposal submission. 7. **Overheads** (overhead is calculated as 30% of the direct costs, but excluding therefrom the cost of all equipment identified in the application
Funding of public-private partnerships allowed	Yes Irish-based applicants may participate in a consortium of public and private partners. Private partners may not request funding directly from Research Ireland.
Further guidance	**State Aid:** Applicants are advised that funding awarded by Research Ireland under the European Partnership for Personalised Medicine (EP PerMed) Programme will be subject to, and must comply with, State aid rules and the conditions of the EU Commission General Block Exemption Regulation (GBER). Funding will be awarded to successful applicants under Article 25, in respect of aid for research and development projects. For further details please consult: **Taighde Éireann-Research Ireland Research and Innovation Scheme 2021-2026**

Israel (CSO-MOH)

Funding Organisation	**The Chief Scientist Office of the Ministry of Health, (CSO-MOH) -** http://www.health.gov.il/Subjects/research/International_cooperations/Pages/default.aspx
Initial funding pre-commitment	320.000 €
Regional/National contact for the EP PerMed JTC2027	Liron Even-Faitelson Liron.ef@moh.gov.il +972-2-5082168
Eligible institutions	Israeli universities, research centres and hospitals CSO-MOH cannot fund private partners
Additional eligibility criteria	PI should hold a Ph.D., M.D., D.M.D. or equivalent degree and employed by an eligible institution. Research will not be funded simultaneously by CSO-MOH on more than one grant (European network or national). Researchers can not apply for more than one grant from any European network funded by CSO-MOH or submit more than one proposal for any single program. Please see detailed instructions at: **http://www.health.gov.il/Subjects/research/International_cooperations/Pages/default.aspx**
Eligible costs	Personnel (students, technicians; applicants excluded); animals, materials and consumables; travel (up to 5%); overheads 10%. No computers and permanent equipment.
Funding of public-private partnerships allowed	Yes
Further guidance	**Prior to submission, researchers must submit to CSO-MOH an abstract approved by their research authority including a detailed budget distribution.**

	This is not the consortia abstract, but an abstract describing the activity of the Israeli researcher within the consortia and a budget table for the Israeli researcher. A template for the abstract can be found here. **Lack of submission of an abstract can lead to disqualification of the whole application, as well as the consortium.** Bioethics approvals, if applicable, need to be submitted with the application or within 4 months following the approval of the application. Please see detailed instructions at: **http://www.health.gov.il/Subjects/research/International_cooperations/Pages/default.aspx**

Israel (IIA)

Funding Organisation	**National Technological Innovation Authority (IIA)**
Initial funding pre-commitment	
Regional/National contact for the EP PerMed JTC2027	
Eligible institutions	
Additional eligibility criteria	
Eligible costs	
Funding of public-private partnerships allowed	
Further guidance	

Italy (IT-MoH)

Funding Organisation	**Italian Ministry of Health, (IT MoH)** - www.salute.gov.it
Initial funding pre-commitment	TBD
Regional/National contact for the EP PerMed JTC2027	int-dgric@sanita.it Simona Carmen Ursu sc.ursu@sanita.it Alessandra Vittoria Lallo av.lallo@sanita.it
Eligible institutions	Only IRCCS (Istituti di Ricovero e Cura a Carattere Scientifico) researchers are eligible to apply. Not eligible for funding: Universities, other research Institutes, companies
Additional eligibility criteria	Maximum funding per project: xxxx euros (to be determined). In case two eligible partners (IRCCS) are involved in the Consortium, the total amount must be shared between them. No more than two partners may receive funding under the same project. • A Principal Investigator (PI) cannot participate in more than one 2027 Joint Transnational Call (JTC) funded by the Italian Ministry of Health. If the PI is already the beneficiary of other active projects funded by the Italian Ministry of Health within European JTC schemes, the researcher is not allowed to submit a new application. • A PI holding an active IT MoH grant may submit a proposal to a new JTC only if the ongoing project has been formally closed prior to the pre-proposal submission deadline. A project is deemed closed only upon submission and formal acceptance by the Italian Ministry of Health of both the final financial report and the final scientific report through the Workflow Research platform. If the ongoing project is expected to conclude within six months from the JTC pre-proposal deadline, the PI must submit a formal declaration stating that no request for project extension will be made. • These eligibility restrictions apply exclusively to individuals serving as Principal Investigators. Co-investigators, collaborators, and other project team members who are not designated as PIs are not subject to these limitations.

	• No more than two Italian PIs are eligible to apply for the same project.
Eligible costs	**Direct Costs:** • Personnel (only temporary contracts or permanent contracts for the number of hours dedicated to the project) Max. 60%. • Consumables/Supplies. • Equipment (only on leasing or rent). • Travel (Max. 30%). • Dissemination activities (Max. 1%). • Publication costs: Max. 2%; Open Access Max 5%. **Other direct costs** such as: • Patients' recruitment costs. • Animals/Model costs. • Coordination costs only for Coordinator **Indirect Costs:** **Overhead** (Max.10%, of direct costs). Other indirect costs are not eligible. Transfer of eligible funds abroad is not allowed. **Subcontracts**: they are allowed ONLY upon approval by the Italian Ministry of Health presenting via Workflow research platform (ER communication code) a request together with the pre-eligibility check form, 20 working days before the pre-proposal submission deadline. Subcontracting cannot involve the core activities of the project. Italian PAOs can be funded as a sub-contractor of an IRCCS if they fulfil the eligibility criteria of the EC.

Funding of public-private partnerships allowed	Yes
Further guidance	• Applicants are required to complete and submit a **pre-eligibility check form** to the Italian Ministry of Health using the Workflow Research platform (ER communication code), before submitting their pre-proposal to the Joint Call Secretariat (JCS). The completed form has to be submitted **no later than 20 working days before the pre-proposal submission deadline**. • If subcontracting is envisaged, it must be explicitly requested and pre-approved by the Italian Ministry of Health as part of the eligibility clearance process. Such re-quests must be submitted alongside the pre-eligibil-ity check form. • Changes to the project acronym or budget declared in the pre-submission eligibility check are not permitted. • The mandatory pre eligibility check form and the GDPR Article 13 Information Notice can be downloaded at the following link: **https://www.salute.gov.it/new/it/tema/sistema-ricerca-del-ssn-enti-e-finanziamenti/inter-nazionalizzazione-della-ricerca-biomedica/** • Applicants will receive written notifications of their eligibility status. • After completion of the JTC peer review process and endorsement of the final (scientific) ranking list by the Call Steering Committee, the Italian Ministry of Health will contact the PIs of the awarded projects for the necessary follow-up actions. • Submission of final scientific and financial reports at Italian Ministry of Health will be required. Further information on the rules and guidelines of the Italian Ministry of Health can be found at **https://www.sa-lute.gov.it/new/it/tema/sistema-ricerca-del-ssn-enti-e-finanziamenti/internazionalizzazione-della-ricerca-biomedica/**

Italy (Friuli Venezia Giulia)

Funding Organisation	**Regione Autonoma Friuli Venezia Giulia** - https://www.regione.fvg.it/
Initial funding pre-commitment	250.000 €
Regional/National contact for the EP PerMed JTC2027	Ketty Segatti, 040 3775206, ketty.segatti@regione.fvg.it Luciana Grimani, 040 3775274, luciana.grimani@regione.fvg.it
Eligible institutions	**Eligible institutions:** A. **Academic partners**: universities and research institutes located in Friuli Venezia Giulia region that meet the definition of "research organisation" as referred to in EU state aid legislation (2014/C 198/01); B. **Healthcare organisations**: IRCCS, Local Health Authorities and Integrated University and Health Authorities (Aziende Sanitarie e Aziende Sanitarie Universitarie) C. **For-profit entities**: SMEs and large companies, including spin offs and innovative start ups **Please note:** maximum **two partners** from Friuli Venezia Giulia per project. All applicants must be located in Friuli Venezia Giulia and their activities should take place in the Region. The Principal Investigator (PI) must be affiliated to one of the eligible institutions.
Additional eligibility criteria	**Pre-eligibility check** Friuli Venezia Giulia Region will grant an eligibility clearance to the potential applicants prior to the submission of their pre-proposals. To this end, it is mandatory that the applicants fill out a pre-submission eligibility check form (available on the Friuli Venezia Giulia Region institutional website or on request to **luciana.grimani@regione.fvg.it**) before submitting their proposal to the Joint Call Secretariat. The form must be completed and duly

	signed by the Principal Investigator and the legal representative of the applicant entity and sent to Friuli Venezia Giulia Region (**luciana.grimani@regione.fvg.it**), at least **10 days** before the pre-proposal submission deadline. **Aid intensity** 1. Financing to enterprises is granted in compliance with the provisions of Regulation (EU) No 651/2014. 2. For the JTC2027, the project activity is classified within the scope of industrial research. Since projects are presented by transnational consortia, it is considered that participating enterprises will carry out the project activity in collaboration with a university, or a research organisation or a healthcare and research organisation. Given these premises, the aid intensity applicable is as follows: a) Micro and small enterprises: 80% b) Medium-sized enterprises: 75% c) Large enterprises: 65% 3. To benefit from the aid intensity referred to in paragraph 1, the university, research organization, or healthcare and research organisation must bear at least 10% of the eligible costs and have the right to publish the results of its research. 4. For the purposes of determining the aid intensity for universities, research organizations and healthcare and research organisations, reference is made to the flat-rate calculation as established by Delegated Regulation (EU) No. 1516/2015 of the Commission of 10 June 2015, according to which net revenue is recognized at a flat rate equal to 20% of the total project budget, limiting the contribution rate to 80%. 5. The contributions provided for in this call for proposals cannot be combined with other public contributions and State aid, even under the "de minimis" regime, granted for the same expenses. **State aid requirements:** Companies that participate in the call for proposals must meet specific eligibility requirements in accordance with

	State aid legislation. It is strongly recommended that interested companies read carefully the complete list of requirements available on the institutional web page of Friuli Venezia Giulia region. **Scope of the call:** No limitation is introduced concerning the scope of the call.
Eligible costs	**Eligible costs** • Personnel (determined using standard unit cost tables, as detailed in the Guidelines for Financial Reporting) • Tools and equipment (in amount equal to amortization value, or on leasing in proportion to the actual use for the project) • Qualified consulting services (e.g. for technical-scientific activities of industrial research, studies, design, and similar activities) • Services • Intangible assets (e.g. purchase of patents, know-how, licensing rights) • Prototype construction (e.g. materials, services, processing acquired for the physical construction of prototypes and/or demonstrators) • Consumables • Overheads (general expenses, flat rate of 10% of personnel costs) • Travel For the detailed description of eligible and not eligible costs, read carefully the Guidelines for Financial Reporting (Linee Guida alla Rendicontazione) available on the website of Friuli Venezia Giulia Region.
Funding of public-private partnerships allowed	Yes
Further guidance	**The Region will provide at a later stage the links to specific funding guidelines, the pre-eligibility check form and financial reporting guidelines, which will be made available on the institutional website.**

Italy (Lombardy)

Funding Organisation	**Fondazione Regionale per la Ricerca Biomedica - Regional Foundation for Biomedical Research, (FRRB)**
Initial funding pre-commitment	1.000.000 €
Regional/National contact for the EP PerMed JTC2027	Giulia Maria Rossignolo Piazza Città di Lombardia, 1, 20124 – Milano, Italy Tel.: (+39) 02 67650159 bandi@frrb.it; giuliamaria.rossignolo@frrb.it
Eligible institutions	MAXIMUM TWO PARTNERS from Lombardy PER PROJECT Eligible applicants: 1. Public or Private Italian IRCCS (Scientific Institutes for Health Research, Hospitalization and Health Care) 2. Public Health Care Providers (ASST) 3. Agenzie di Tutela della Salute (ATS) 4. Azienda Regionale Emergenza Urgenza (AREU) 5. Universities - only in partnership with one of the organizations above (1,2,3,4) located in Lombardy and requesting funding to FRRB 6. Research Institutes - only in in partnership with one of the organizations above (1,2,3,4) located in Lombardy and requesting funding to FRRB. **Please note: All applicants must be located in Lombardy and their activities should take place in Lombardy. Enterprises and for-profit Organisations are NOT eligible.**
Additional eligibility criteria	According to internal procedures, the Regional Foundation for Biomedical Research will grant an eligibility clearance to the potential applicants prior to the submission of the pre-proposals. This eligibility check will be based on the verification of a dedicated form ("Eligibility check form"), also available on the FRRB Call webpage, to be completed by the Principal Investigator at least 3 working days before the pre-proposal submission deadline. **FRRB will provide feedback on the "Eligibility check form" ONLY in case of major non-eligibility issues**. In addition,

	FRRB provides an excel sheet to help applicants abide by FRRB funding rules. This form is meant to support the PIs in the elaboration of the proposal budget, but it does not need to be sent to FRRB. **A Principal Investigator (PI) cannot simultaneously hold more than one FRRB active grant.** PIs who are currently FRRB grant holders cannot apply to the EP PERMED JCT2027 unless their previous project is closed before the starting of the JTC 2027 project. A project is considered closed when the final financial and scientific reports have been sent to FRRB. This rule applies only to PIs (grant holders), not to their team members.
Eligible costs	Direct costs: Personnel (for public IRCCS and ASST, ATS and AREU, ONLY staff recruited specifically on the project). Personnel costs of PIs who have a permanent contract (contratto a tempo indeterminato) with their own organization are NOT eligible. Consumables, animals purchase, maintenance and breeding. Equipment (on hire or eligible amortization rate). Travel: max 10% of the total direct costs (overheads and subcontracting costs excluded) Publications (only Open Access): max 5% of the total direct costs (overheads and subcontracting costs excluded). Other direct costs: please insert under this category any other costs, including those related to patient involvement (insurance, reimbursement, etc.). Subcontracting: max 20% of the total direct costs (overheads costs excluded). Indirect costs: Overheads: 20% flat rate calculated on direct costs (subcontracting costs excluded from this calculation).

	FRRB will require the submission of a financial audit certificate together with the final financial report. This cost, to be included under the "Subcontracting" category will be eligible up to a maximum of € 8.000. Only costs generated over the lifetime of the project will be considered eligible.
Funding of public-private partnerships allowed	Yes Please note: Enterprises and for-profit Organisations are NOT allowed to request funding from FRRB.
Further guidance	To this end, it is mandatory that the **applicants fill out and upload on the FRRB platform a pre-submission eligibility check form before submitting their proposal** to the Joint Call Secretariat. It is strongly recommended that the form, completed and duly signed, is uploaded **at least 3 working days before the proposal submission** deadline. Applicants will not be sent written notification of their eligibility status. FRRB will provide feedback on the "Pre-eligibility check form" ONLY in case of major is-sues or non-eligibility.

Italy (Tuscany)

Funding Organisation	**Tuscany Region, (RT)**
Initial funding pre-commitment	300.000 € Anticipated number of potential project partners: 1-2 Max 0.3 M€ per project; if 2 Tuscan partners in same consortium, 0.3M€ will be shared
Regional/National contact for the EP PerMed JTC2027	Teresa Vieri tel +39 0554383289 Monica Malacarne+39 0554382334 Email: eppermed@regione.toscana.it
Eligible institutions	A. Authorities of the Tuscany Health Service-SST (Local Health Authorities, University Hospitals) and the SST bodies that carry out institutional research activities (Fondazione Toscana Gabriele Monasterio and ISPRO Institute for Study, Prevention and Networking Oncology) located in the territory of Tuscany. B. Universities and other research institutes located in the territory of Tuscany. NB: Institutions referring to point B are eligible only in partnership with institutions referring to point A. The Principal Investigator must be affiliated to one of the eligible bodies
Additional eligibility criteria	Tuscany Region will grant an eligibility clearance to the potential applicants prior to the submission of their pre-proposals. The eligibility check will be performed by Tuscany Region offices after receiving a dedicated form (available on Tuscany Region institutional website or on request to eppermed@regione.toscana.it) duly filled and signed by the Tuscan Principal Investigator and the legal representative of the applicant entity. The form should be sent to Tuscany Region (eppermed@regione.toscana.it), **at least 10 days before the pre-proposal submission deadline**.
Eligible costs	Only costs generated over the lifetime of the project will be considered eligible: - Personnel (ad hoc temporary contracts ONLY); - Consumables (no limit);

	- Equipment (on hire/leasing or eligible amortisation rate ONLY); - Travel (Up to 10% of the requested fund) Travel expenses and subsistence allowances associated with activities only linked to the project; - Other direct costs: • dissemination of results (publications, organization of meetings/workshops etc.- up to 5% of the requested fund); • patient costs - subcontracting (up to 20%of the direct costs of the projects) - Overheads (up to 10% of the direct costs of the project excepted subcontracting).
Funding of public-private partnerships allowed	Yes Please note that for private partners coming from the Tuscany Region, Tuscany Region is only providing funding to applicants from non-profit research organisations.
Further guidance	Financial guidelines: Decreto dirigenziale n. 27322 del 20.12.2023 **https://www301.regione.toscana.it/bancadati/atti/DettaglioAttiD.xml?codprat=2023AD00000030275**

Latvia

Funding Organisation	**Latvian Council of Science, (LZP)**
Initial funding pre-commitment	600.000 €
Regional/National contact for the EP PerMed JTC2027	Uldis Berkis E-mail: Uldis.Berkis@lzp.gov.lv Tel.: +371-29472349
Eligible institutions	Only the following legal persons are eligible: 1) Research institutions registered in the Latvian Registry of Scientific Institutions, e.g. research institutes and universities, and must have the status of Research and knowledge dissemination organization (Regulation EC 651/2014). 2) Business enterprises entered into the Latvian Commercial registry as companies, assuming they are eligible to do the specific research and have specific capacity and resources to do the research in Latvia and have their main activity in Latvia. Limitations of EU legislation apply (Regulation 651/2014) together with financial reporting requirements, in this case it is state aid. Two previous statements with sworn auditor's approval should be provided, and they must reflect the correspondence to the regulation and provide the evidence of previous scientific activity and presence of capacity. *Enterprises not having closed two annual financial periods are not eligible.*
Additional eligibility criteria	**Maximum funding allowed: 100.000 EUR per year per Latvian partner = grant of 0.3M for a 3-year project, 0.2M for a 2-year project** Latvia allows max 2 Latvian partners per proposal. They must be fully independent on legal, financial and personnel basis.

	All topics of the call are eligible. Applicants for State aid must send before the call deadline (both 1st and 2nd stages) to the e-mail address lzp@lzp.gov. lv, stating the acronym and the title of the project, applicant name and registration number in Latvia, the following document: a certification that the applying legal person does not correspond to the criteria laid down in laws and regulations to be subject to insolvency proceedings at the request of the creditor. It must be electronically signed by valid legal representative (s). Upon request applicants for State aid must provide all requested documents to evaluate the financial situation and financial viability. Undertakings in difficulty are not eligible for funding. (Regulation 651/2014). In case of State aid the undertakings are assessed for eligibility at each of the application stages and at the conclusion and during execution of the contract with LCS for project funding. If the eligibility criteria are not fulfilled, project funding cannot be approved or continued. Final audit according to the LCS regulations. LCS operates only through a Latvian bank account. *LCS funds only research, no training nor implementation. LCS is not funding any activity beyond experimental development.*
Eligible costs	Personnel costs incl. taxes; • Consumables, animals; • Subcontracts (up to 25% of direct costs), needs detailed justification, includes all external services, project core activities cannot be subcontracted; • Equipment (only depreciation costs during project directly attributable to project tasks); • Replaceable and fully consumable during project elements of equipment; • Travels (according to travel plan);

	Indirect costs (up to 25% of direct costs excluding subcontracting).
Funding of public-private partnerships allowed	Yes, LCS can fund projects where eligible public research organisations collaborate with eligible enterprises, but does not fund partnerships per se.
Further guidance	Support is provided according to Provisions Nr 259, 26.05.2015 of the Latvian Cabinet of Ministers **http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petnieciibas-un-tehnologiju-joma** These provisions should be respected without exceptions. The maximum rates should respect the Provisions. The requirements in the provisions to specific applicant groups must be respected. Annual financial and scientific reporting is mandatory. To receive funding by LCS, Consortium agreement duly signed should be presented. Application for the state aid must be submitted before the start of the project which is stated in the consortium agreement. Enterprises shall provide audited statements of 2 previous closed financial periods on request. Final audit according to the LCS regulations.

Lithuania

Funding Organisation	**Lietuvos mokslo taryba / Research Council of Lithuania, (LMT)** - info@lmt.lt
Initial funding pre-commitment	300.000 €
Regional/National contact for the EP PerMed JTC2027	Živilė Ruželė, Tel.: +37 067 614383 E-mail: zivile.ruzele@lmt.lt
Eligible institutions	Institutions eligible for funding include Lithuanian research and higher education institutions listed in the Register of Education and Research Institutions; public healthcare institutions; the Academy of Sciences referred to in the Law on Science and Studies; and other state public institutions, such as national libraries, archives, and museums. The eligible beneficiary institution, acting as the grant holder, manages the state budget funds allocated to the project in accordance with the applicable legal acts and represents the project partners, where applicable. For these purposes, a project partner means a public or private legal entity that, together with the eligible beneficiary institution, has created the conditions necessary for the implementation of the project. Eligibility criteria for Lithuanian participants are listed the national call text that is published in parallel with the JTC2027 on the LMT website **here**.
Additional eligibility criteria	The Principal Investigator (PI) must hold a PhD degree. Principal Investigators based in Lithuania may participate in only one proposal submitted under this call. The beneficiary institution is responsible for employing the Principal Investigator for the duration of the project. The PI's workload must be no less than 20 hours per month, multiplied by the number of months of the project's duration.

	Personnel costs must be calculated using the hourly rates approved by the Chairman of the Research Council of Lithuania. All other general rules for the competitive funding administered by the Research Council of Lithuania apply: **https://www.e-tar.lt/portal/lt/legalAct/0a8bead0577611e9975f9c35aedfe438/asr** LMT has no limitations concerning the scope of the call, i.e. 1) Somatic personalised cell therapeutics; 2) Gene therapeutics; 3) Combined personalised cell- and gene therapeutics in the form of genetically modified cells; 4) Novel biological products. All topics are eligible.
Eligible costs	Within a single project proposal, the maximum funding amounts are as follows: • Up to EUR 150,000 for a regular consortium partner • Up to EUR 200,000 for a coordinator, or for two eligible regular partners within a consortium • Up to EUR 250,000 for a coordinator and one eligible regular partner within a consortium In all cases, if the eligible beneficiary institution(s) (i.e., implementing institution(s)) include a "project partner" (please refer to the section Eligible Institutions), the total requested budget, while respecting the maximum limits per project, must also include the budget allocated to the associated "project partner". Only costs incurred during the official project duration and directly related to project implementation are considered eligible. These include staff, travel, consumables, subcontracts, contractual research, consultancy, equipment and instruments, dissemination of results, data handling and analysis, overheads (up to 20 % from direct costs).
Funding of public-private partnerships allowed	Yes Our organisation (LMT) can provide financial support to for-profit private partners; however, this support cannot be provided directly.

	Any public or private legal entity may act as a "project partner" in collaboration with an eligible beneficiary institution (see section Eligible Institutions). Public entities participating as project partners receive funding through the grant holder (beneficiary institution), in accordance with applicable funding rules.
Further guidance	Submission of the proposal at the national level is not required at the application stage. However, following a positive funding decision, the grant-signing institution and the Principal Investigator (PI) must complete and submit a national document (template available **[at this link]**) containing the following information: • A more detailed planned budget • Foreseen dissemination and communication activities • Expected project outputs and contributions from the granted research team (e.g., scientific publications, patents, etc.) In addition, both midterm and final reports must be submitted at the national level in accordance with the requirements of the Research Council of Lithuania.

Luxembourg

Funding Organisation	**Luxembourg National Research Fund, (FNR)**
Initial funding pre-commitment	300.000 €
Regional/National contact for the EP PerMed JTC2027	Dr. Ing. Gideon Gießelmann Luxembourg National Research Fund Maison du Savoir (8th floor) 2, place de l'Université L-4365 Esch-sur-Alzette T +352 691 362 805 Gideon.giesselmann@fnr.lu
Eligible institutions	Eligible institutions Universities, Research Institutions, other research actors under the conditions specified in the FNR eligibility rules: https://www.fnr.lu/fnr-beneficiaries/
Additional eligibility criteria	Project duration: The maximum amount of requested funding per project is 300.000 EUR for a total period of three years. If the project involves the recruitment of a PhD student, the PhD candidate could be supported for up to four years (see **FNR INTER guidelines**). **Eligibility for proposals and applicants is determined by the FNR regulations in force on the submission date**: All eligibility rules and criteria can be found in the **FNR INTER guidelines** and in the **FNR General rules and Regulations**. Only PIs who align with the FNR requirements for PIs and supervisors are eligible to apply. As a specific rule for this call, Luxembourg PIs are limited to submit one proposal per Luxembourg PI. Luxembourg PIs who have been granted an EPPerMed inproject are not eligible to apply to the same call at the following call deadline (in case of annual deadlines) and/or the following 13 months (in case of biannual or ongoing deadlines).

	Forms to be submitted: Proposals must be submitted by the coordinating institutions' administrations (not by the PI) in electronic format to the online submission system (FNR Grant Management System) the **latest 7 days after the deadline** as the consortium application is submitted. Please select the "INTER" – "EP PerMed" funding instrument when creating the administrative application. The FNR INTER guidelines provide details about the basic administrative data and the documents to be provided. General rules and regulations of FNR apply: https://www.fnr.lu/how-we-fund-research/
Eligible costs	Please refer to the **FNR financial regulations** for eligible costs.
Funding of public-private partnerships allowed	Yes (though the FNR cannot fund the private partner)
Further guidance	Applicants should contact the national contact point before submitting their application.

Norway

Funding Organisation	**The Research Council of Norway, (RCN) -** www.forskningsradet.no
Initial funding pre-commitment	1.600.000 €
Regional/National contact for the EP PerMed JTC2027	Karianne Solaas E-mail: **kso@rcn.no** Tel.: +(47) 945 35 380
Eligible institutions	Norwegian universities, university colleges, hospitals, independent research institutes, user organisations and other publicly funded research groups, and private industry. The Research Council cannot award support to an enterprise that is defined as an "undertaking in difficulty" under the state aid rules (see the "Definition of 'undertaking in difficulty" on our website). "Enkeltpersonforetak", that is Norwegian companies with sole proprietorship, cannot participate as coordinator.
Additional eligibility criteria	Clinical research/trials and translational studies allowing rapid implementation into public health-related decisions or into the clinic are encouraged. SME or other industrial partner is funded with up to 50% of their eligible project costs (see details in the State Aid rules, Article 25). All applicants and partners must comply with the State Aid rules. All projects are to be carried out as effective collaboration between the partners. Undertakings (companies) that participate in the consortium must also not receive indirect state aid in the form of advantageous conditions for cooperation with the research institutions taking part in the consortium. Conditions for awarding state aid https://www.forskningsradet.no/en/state-aid/
Eligible costs	Payroll expenses, procurement of R&D services, consumables, network measures. Please follow the RCN research project budget rules in the following link: **https://www.forskningsradet.no/en/financing/how/budget**. However, PhD fellowships are not eligible within the RCN funding, and if a postdoc fellowship, it must be sought for 3 years. For funded projects, the contractual budget will be in Norwegian krone (NOK) using the official exchange rate from

	the European Central Bank at the pre-proposal deadline. Depending on the volume of submitted and eligible projects, up to 25% additional funding may be allocated to the call to fund additional projects on the ranking list.
Funding of public-private partnerships allowed	Yes
Further guidance	The Norwegian part of one project may apply 250.000 - 350.000 € for a three-year project. However, if the Norwegian partner is the project coordinator, a maximum of 450.000 € may be applied for a three-year project. If two Norwegian partners apply for funding in the same project, the Norwegian partners must share the total amount.

Poland

Funding Organisation	**Narodowe Centrum Badan i Rozwoju / National Centre for Research and Development, (NCBR) -** www.ncbr.gov.pl
Initial funding pre-commitment	1.100.000 €
Regional/National contact for the EP PerMed JTC2027	Anna Stępień, +48 22 39 07 210, anna.stepien@ncbr.gov.pl
Eligible institutions	The following entities are eligible to apply: • Enterprises - SME and Large[6] • Research organisation[7], • Group of enterprises composed of two enterprises, • Group of entities composed of one research organisation and one enterprise, • Group of entities composed of two research organisations
Additional eligibility criteria	No limitations concerning the scope of the call. All topics to be funded.

[6] As defined in Annex I to Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty (hereinafter referred to as "Commission Regulation (EU) No 651/2014");

[7] as defined in Article 2(83) of Commission Regulation (EU) No 651/2014, and in Article 37(1) of the Act of 30 April 2010 on the National Centre for Research and Development (Polish Journal of Laws 2024, item 1170 as amended), in conjunction with Article 7(1)(1, 2, 4, 5, 6, 6a, 6b, 6c, 8) Act of 20 July 2018 of the Law on Higher Education and Science (Polish Journal of Laws 2024, item 1571 as amended).

	For a group of entities to participate as an Applicant in the call, it must formally exist on the date the pre-proposal is submitted. This existence must be evidenced by an agreement made by the members - at least conditionally - to create the group of entities (consortium). Participating entities must be established under Polish law either as a legal person[8] or as a sole trader[9] and must conduct business, R&D activity or other activity on the territory of the Republic of Poland, confirmed by an entry into the relevant register[10]. For enterprises it is strongly advised to state in the pre-proposal application form the KRS (National Court Register) number of the enterprise and the size of the enterprise (micro/small, medium, large). Please note that group of entities counts as at least two project partners from Poland (it meets the limit on the number of participants from the same country, please refer to call text for details). All proposals must be aligned with national regulations, inter alia: • The Act of 20 July 2018 - Law on Higher Education and Science (Polish Journal of Laws 2024, item 1571 as amended; • The Act of 30 April 2010 on the National Centre for Research and Development (Polish Journal of Laws 2024, item 1170); • The Regulation of the Minister of Science and Higher Education of 19 August 2020 on granting state aid by the National Centre for Research and Development (Polish Journal of Laws 2025, item 783 as amended), which is in line

---

[8] Legal person - an entity other than a natural person that has the legal capacity to hold and to exercise legal rights and obligations within a certain legal system, in particular to enter into contracts, sue, and be sued.

[9] Sole trader (sole proprietor, self-employed person) – a natural person conducting economic activity in their own name and on their own account, including as a partner in a civil law partnership (spółka cywilna).

[10] If applicable. Does not apply to legal persons that are not obliged to register in a relevant Polish official register according to Polish law.

	with the Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty (General Block Exemption Regulation); • The Regulation of the Minister of Science and Higher Education of 17 September 2010 on the detailed mode of performance of tasks of the National Centre for Research and Development (Polish Journal of Laws 2010 No. 178, item 1200 as amended); NCBR may enter into a project contract provided that the participating entity: 1) is not excluded from applying for funding on the basis of: a) Article 207(4) of Act of 27 August 2009 on Public Finance (Polish Journal of Laws 2025, item 1483 as amend - ed); b) Article 12(1)(1) of the Act of 15 June 2012 on the consequences of entrusting work to foreigners staying illegally in the territory of the Republic of Poland (Polish Journal of Laws 2025, item 1567 as amended); c) Article 9(1)(2a) of the Act of 28 October 2002 on the liability of collective entities for acts prohibited under penalty (Polish Journal of Laws 2024, item 1822 as amended); 2) is not an entity subject to an obligation to repay aid because the European Commission has declared such aid unlawful and incompatible with the internal market, 3) is not in arrears with payments of public dues or with social security and health insurance contributions, 4) is not an undertaking in difficulty[11] within the meaning of EU state aid rules and is not under receivership, 5) is not subject to exclusion from applying for funding due to sanctions. In justified cases, the composition of group of entities may be changed before the funding decision is issued by NCBR. Any changes must meet the call's eligibility criteria and be approved in advance by the international project consortium, the call secretariat, NCBR, and any other funding institutions involved. Changes must also respect the principle of equal treatment of applicants.

[11] The definition of an undertaking in difficulty is set out in Article 2(18) of Regulation (EU) No 651/2014

	In light of the European Commission's ongoing work on a regulation intended to replace Regulation (EU) No 651/2014, the National Centre for Research and Development (NCBR) informs applicants that the conditions govern-ing the provision of support set out in this documentation may be amended following the entry into force of the new regulation
Eligible costs	Maximum funding per grant awarded to a project partner: • up to 350.000 EUR for one Polish partner in the project • up to 400.000 EUR for all Polish partners in the project. The eligible costs shall be the following: ***For research organisations:*** 1. **personnel** 2. **consumables** 3. **equipment** 4. **travel** 5. **other direct costs** - please refer to cost eligibility guide (przewodnik kwalifikowalności kosztów) for more de-tails 6. **subcontracting** – used exclusively for the research activity; this cost category shall not exceed 70% of all eli-gible costs of a project 7. **overheads** – incurred indirectly as a result of the research project. That costs should account 25% of all eligib-le direct costs and are counted as a multiplication by percentage given above (called x%) and the rest of direct costs for research organizations, excluding subcontracting (6); It means 7 = (1+2+3+4+5)x25%. ***For enterprises:*** 1. **personnel** 2. **equipment** 3. **other direct costs**: please refer to cost eligibility guide (przewodnik kwalifikowalności kosztów) for more de-tails 4. **subcontracting** – used exclusively for the research activity; this cost category shall not exceed 70% of all eligible costs of a project 5. **overheads** – incurred indirectly as a result of the research project. That costs for enterprises include costs related to consumables, travel and other direct costs. Additional overheads costs should account 20% of eligible direct project

costs and are counted as a multiplication by percentage given above (called x%) and the rest of direct costs; It means 5 = (1+2+3+4)x20%.

For more details on eligible costs, applicants are advised to check cost eligibility guide (przewodnik kwalifikowalności kosztów) in the call announcement on NCBR webpage.

Funding quotas for Polish participants may reach up to 100% for research organisations.

For enterprises, the quota will be determined on a case-by-case basis, taking into account company size and the type of research and development activity, pursuant to the provisions of the Regulation of the Mi-nister of Science and Higher Education of 19 August 2020 on granting state aid by the National Centre for Research and Development (Polish Journal of Laws 2025, item 783 as amended). In any case Industrial Re-search and Experimental Development are eligible for funding.

In any case Industrial Research and Experimental Development are eligible for funding. Other activities (e.g. coordination, dissemination, management) shall not be included into separate tasks.

Maximum funding percentages:

	Large Enterprises	Medium Enterprises	Small Enterprises	Universities and research organizations
Basic Research	Not eligible	Not eligible	Not eligible	Not eligible
Industrial/Applied Research	Up to 50+5/15/25 (max 75 %)	Up to 50+10+5/15/25 (max 80 %)	Up to 50+20+5/15/25 (max 80 %)	Up to 100 %
Experimental development	Up to 25+5/15/25 (max 50 %)	Up to 25+10+5/15/25 (max 60 %)	Up to 25+20+5/15/25 (max 70 %)	Up to 100 %

For entrepreneurs independently undertaking projects at the national level (meaning there is no Polish group of entities or Polish group of enterprises), there is no possibility of increasing the intensity of state aid by 15 percentage points for industrial research and experimental development based on the condition of effective cooperation between entrepreneurs or between entrepreneurs and research organisations.

	In justified cases, the composition of group of entities may be changed before the funding decision is issued by NCBR. Any changes must meet the call's eligibility criteria and be approved in advance by the international project consortium, the call secretariat, NCBR, and any other funding institutions involved. Changes must also respect the principle of equal treatment of applicants. Polish participants shall submit to NCBR a copy of signed international consortium agreement before signing the grant agreement with NCBR.
Funding of public-private partnerships allowed	Yes
Further guidance	National Application Form (NAF) After international evaluation of full proposals and the selection of projects to be funded, Polish participants will be invited to submit a National Application Form (NAF). The NAFs will be examined for the appropriateness of funding requested. The Polish participants are obliged to use the rate of exchange of the European Central Bank dated on the day of opening of the call. If more than one Polish entity participates in the project, the national application is submitted by a consortium (group of entities) of all Polish partners. Document templates are available at: **https://www.gov.pl/web/ncbr/wniosek-krajowy-w-lsi** We encourage you to learn about and use our "PartFinder" (Partner Search Tool), which allows you to match science and industry entities from around the world with each other. The search engine is available at: **https://partfinder.ncbr.gov.pl/** Detailed information about scope, financial rules, national procedure and national regulations is available on the NCBR's homepage: **https://www.gov.pl/web/ncbr/platforma-konkursowa/**

Portugal (FCT)

Funding Organisation	**Fundação para a Ciência e a Tecnologia, (FCT)** - EPPerMed@fct.pt
Initial funding pre-commitment	
Regional/National contact for the EP PerMed JTC2027	
Eligible institutions	
Additional eligibility criteria	
Eligible costs	•
Funding of public-private partnerships allowed	
Further guidance	•

Portugal (Azores)

Funding Organisation	**Vice-Presidency of the Regional Government of Azores, (VP-GRA)** - info.drcid@azores.gov.pt
Initial funding pre-commitment	100.000 €
Regional/National contact for the EP PerMed JTC2027	Sara de Viveiros Pavão, +351 296 308 903, sara.v.pavao@azores.gov.pt
Eligible institutions	Higher education institutions, their institutes, and R&D units Private non-profit institutions whose main purpose is R&D activities Other public and private, non-profit institutions that develop or participate in scientific research activities Entities of the Regional Scientific System (SCTA)
Additional eligibility criteria	Decreto Regulamentar Regional n.º 17/2012/A de 4 de julho de 2012
Eligible costs	- Direct personnel costs, including all costs with social security contributions, fees and taxes provided by law for personnel working for IP under an employment contract. Other types of contracts are permitted as long as the work carried out is under the control of IP, belongs to the Institution and the costs are identical to those arising from an employment contract; - Direct Subcontracting costs, which cannot exceed 30% of the total value of eligible project expenses; - Other direct costs, including travel costs, accommodation and expected subsidies, acquisition of equipment, renting and leasing, other goods and services; - Indirect costs, which are calculated through a flat rate of 7% on direct personnel costs and other eligible direct costs, excluding direct subcontracting costs. There is no need to submit specific documentation;
Funding of public-private partnerships allowed	Yes

Further guidance	Guidelines for the participation of RAA research teams in European Partnerships funded by VP-GRA/DRCID. The regional research teams selected in the pre-proposal stage, will have to submit a Declaration of Honour to be able to proceed to the 2nd stage of the evaluation. The template of this declaration will be provided by the DRCID team. The Portuguese funding agencies in this call reserve the right to evaluate the possibility of transferring application(s) to the other national funding agency, when necessary, for example in the following conditions: 1. if an application is considered non-eligible by the funding agency selected by the candidate institution, but is eligible by the other Portuguese funding agency; 2. 2. if it is necessary to maximize the number of funded national projects.

Romania

Funding Organisation	**Executive Agency for Higher Education, Research, Development and Innovation Funding, (UEFISCDI)**
Initial funding pre-commitment	1.000.000 €
Regional/National contact for the EP PerMed JTC2027	Mihaela Manole mihaela.manole@uefiscdi.ro Nicoleta Dumitrache nicoleta.dumitrache@uefiscdi.ro
Eligible institutions	Eligible entities for funding are universities, public institutions, R&D national institutions, joint-stock companies, SME's and Large companies, NGOs (associations, foundations, etc.), others. Funding rates vary in accordance with state aid legislation. For more information: **https://uefiscdi.gov.ro/parteneriate-si-misiuni-europene** A person, as project manager, regardless of whether the Romanian institution is a project coordinator or partner, at the level of a transnational competition, can participate in a single project proposal.
Additional eligibility criteria	250.000 euro in case a Romanian institution is the Coordinator (together with other Romanian partner(s) – if it is the case); 200.000 for one/all Romanian partner(s) participating in a proposal.
Eligible costs	a. Staff costs; b. Logistics expenses - Capital expenditure;

	- Expenditure on stocks - supplies and inventory items; - Expenditure on services performed by third parties cannot exceed 25 % of the funding from the public budget. The subcontracted parts should not be core/substantial parts of the project work; c. Travel expenses; d. Overhead (indirect costs) is calculated as a percentage of direct costs: staff costs, logistics costs (excluding capital costs and cost for subcontracting) and travel expenses. Indirect costs will not exceed 25 % of direct costs.
Funding of public-private partnerships allowed	Yes accordance with state aid legislation. For more information: https://uefiscdi.gov.ro/parteneriate-si-misiuni-europene
Further guidance	

Slovak Republic

Funding Organisation	**Centrum vedecko-technických informácií Slovenskej republiky, (CVTI SR)**
Initial funding pre-commitment	600.000 €
Regional/National contact for the EP PerMed JTC2027	Maros Halama, maros.halama@cvtisr.sk, +421 917 733 475
Eligible institutions	Legal entities established in the Slovak Republic, such as public or private research and academic institutions, higher education institutions, SMEs, public sector entities, and other relevant organizations actively involved in research, development, and innovation. • Private sector entities (entrepreneurial/business sector) • Research institutions (e.g. the Slovak Academy of Sciences and its institutes) • Academic sector (e.g. universities and higher education institutions) • Public administration bodies and organizations established by them, including local and regional government authorities CETPartnership Joint Call 2026 page 2 of 4 EUROPEAN Partnership: cetpartnership.eu • Non-governmental non-profit organizations • Cluster organizations Large enterprises, medium enterprises, small enterprises, Universities, public research organisations, public authorities, associations without economic activities, NGOs with industrial and applied research or experimental development and innovations (basic research is not supported.
Additional eligibility criteria	Submission of the pre-proposal and full proposal to the JTC 2027 Call Secretariat/platform only.

	Following the receipt of the formal international funding recommendation, applicants will be required to submit a separate application for national funding via the national submission platform. This serves as the final formal step, with the official funding decision issued by CVTI SR once the project has been successfully recommended by the Partnership. All Slovak applicants must ensure that their proposed activities are in accordance with the national strategic framework, specifically the: Strategy for Financing the ERDF, ESF+, CF, FST, and ENRAF 2021–2027. The minimum funding amount per Slovak project partner is 100 000 EUR. The maximum funding amount is 300 000 EUR per Slovak partner. This maximum amount can go up to 350 000 EUR if the Slovak partner acts as the project coordinator. If a single project involves two Slovak partners, their combined maximum funding is 450 000 EUR in total. These amounts can be further increased by up to 15 000 EUR if a partner submits a patent, trademark, or design application, and/or publishes project results in an internationally indexed (peer-reviewed) scientific journal (e.g., WoS/Scopus). All Slovak entities must have their contractual financial matters settled with CVTI SR by the end of 2029.
Eligible costs	The funding rates are in accordance with the national strategic framework, specifically the: Strategy for Financing the ERDF, ESF+, CF, FST, and ENRAF 2021–2027. Link: **Stratégia financovania EFRR, ESF+, KF, FST a ENRAF na programové obdobie 2021 - 2027 | Ministerstvo financií Slovenskej republiky** Public administration bodies, including local and regional government authorities, are eligible to participate; however, they are not eligible to receive funding and therefore cannot have a budget allocated to them. Entities not established in the Slovak Republic and applications from individuals (natural persons) will not be accepted. Only costs that are essential to the project implementation and are directly related to its activities and timeline are eligible. Overheads are not eligible.

	All costs must be fully utilized and accounted for by the end of 2029. Eligible costs: • Personnel costs (salaries of researchers, technicians and other support staff employed by the beneficiary, to the extent that they are involved in the project; • Costs of instruments and equipment; • Costs for contract research, technical knowledge and patents purchased or licensed from external sources under market conditions, as well as costs for consultancy and equivalent services used exclusively for the project.
Funding of public-private partnerships allowed	Yes
Further guidance	General eligibility rule: All expenditures incurred by Slovak project participants must comply with: • Programme Slovakia, specifically Priority 1P1 Science, Research and Innovation, Specific objective RSO1.1: Development and enhancement of research and innovation capacities and the uptake of advanced technologies, Measure 1.1.3: Support for international cooperation in the field of research, development and innovation • The provisions of the State Aid Scheme to Support Partnerships in the Field of Research, Development and Innovation under the Programme Slovakia; • Strategy for Financing the ERDF, ESF+, CF, FST, and ENRAF 2021–2027. Slovak applicants are advised to thoroughly familiarize themselves with the Guide for Applicants in European Co-funded Partnerships and Guide to Eligibility of Expenses under the Programme Slovakia, as the planned co-financing will be provided through this programme. It is further recommended that at least 30% of the Slovak applicant's total budget be dedicated to the actual performance of research activities. The proposed research activities must be carried out in Slovakia, and their results must be applicable and utilized within the Slovak Republic's environment. The proposed project activities must be in line with the priorities defined in the Research and Innovation Strategy for Smart Specialisation of the Slovak Republic 2021-2027 (SK RIS3 2021+), which serves as the strategic framework for research, development and innovation investments in Slovakia.

	All Slovak entities must have their contractual financial matters settled with CVTI SR by the end of 2029. Programme Slovakia 2021-2027, Research and Innovation Strategy for Smart Specialisation of the Slovak Republic 2021-2027 (SK RIS3 2021+), State Aid Scheme to Support Partnerships in the Field of Research, Development and Innovation under the Programme Slovakia. No change of applicant institution is allowed between the stages. The information given in the pre-proposal is binding and no major changes regarding the proposal's content or objectives are allowed between the pre-proposals and full proposals (if invited to stage 2) including the proposed budget. However, a limited number of minor administrative changes including small budget reshuffles may be allowed. Any modification must be communicated with CVTI SR and ensure that the total funding requested in the full proposal does not exceed the amount declared in the pre-proposal stage. All Slovak applicants are strongly advised to contact the CVTI SR's contact points before submitting their pre-proposals. Programme Slovakia SK RIS3 2021+, Strategy for Financing the ERDF, ESF+, CF, FST, and ENRAF 2021–2027 State Aid Scheme to Support Partnerships in the Field of Research, Development and Innovation under the Programme Slovakia. **Dokumenty | Eurofondy 2020+** **https://vaia.gov.sk/sk/strategia-inteligentnej-specializacie-ris3-2/** **Stratégia financovania EFRR, ESF+, KF, FST a ENRAF na programové obdobie 2021 - 2027 | Ministerstvo financií Slovenskej republiky** **Schéma štátnej pomoci na podporu partnerstiev v oblasti vedy, výskumu a inovácií v rámci Programu Slovensko | Ministerstvo školstva, výskumu, vývoja a mládeže Slovenskej republiky**

Spain (ISCIII)

Funding Organisation	**National Health Institute Carlos III, (ISCIII)**
Initial funding pre-commitment	2.500.000 €
Regional/National contact for the EP PerMed JTC2027	María Adrio Lorente eppermed@isciii.es +34 918222868
Eligible institutions	Eligible Institutions: • Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS). Accredited according to the RD 279/2016 (These institutions may manage research via a foundation regulated according to the Spanish Act 50/ 2002, of December 26th). See the list of IIS in this link. • Hospitals or public health administration of the Spanish National Health System (SNS). These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation's statutes may be submitted). • CIBER. Team members applying to the call must be from at least two groups belonging to CIBER in two different home institutions and one of these two should be a Hospital, primary health care or public health administration of the Spanish National Health System (SNS) or Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados). Please contact CIBER (pai@ciberisciii.es) for more information related to CIBER's eligibility. • Public Research Institutions (OPIs) as defined in article 47 of Law 14/2011, of 1 June, in accordance with the provisions of Royal Decree 202/2021, of 30 March, Private health entities and institutions, public Universities and private Universities with proven R&D activity capacity, other public R&D centres. These entities can only participate if they apply together with hospitals, primary health care or public health administration of the Spanish National Health System (or Accredited Health Research Institutes (IIS) in the same proposal. It is not allowed for

	these entities to apply independently, thus there must be two beneficiary Spanish institutions requesting funding to ISCIII in the same proposal. • Applicants from ISCIII are eligible in the same conditions as Public Research Institution (OPI) above-mentioned. Eligibility criteria from "Líneas Estratégicas de Investigación en Salud" 2027 Intramural apply.
Additional eligibility criteria	**NOT eligible institutions:** • Those declared by the AES 2027 as ineligible to receive funds by ISCIII. • Particularly for this call, it will not be eligible the National Technological Centres and National Centres for supporting technological innovation that are inscribed in the Register according by RD 2093/2008, of 19 December. **IMPORTANT** • A maximum of two different partners requesting funding from ISCIII may participate in the same project proposal. Same beneficiary institution cannot participate with more than one partner in the same project proposal.
Eligible costs	**Personnel costs:** • Personnel costs will be eligible for contracts with the needed professional category (superior technician, BSc (grado), MSc (máster), PhD (doctor) for the project development accordingly to the published salary tables in ISCIII's webpage. Personnel cost will precisely adhere to the updated salary tables, No amounts other than those specified in the applicable salary tables, whether higher or lower, will be considered. • Contracts for PhD students will be done in the framework of National Subprogramme for Training (**scholarships are not eligible).** • Personnel costs will NOT be eligible when they correspond to civil servants or the equivalent personnel (as specified in AES 2027) either employed by the beneficiary entities or belonging to the research team. • The hiring of permanent personnel already belonging to the beneficiary entity or members of the research team will not be considered eligible expenses, unless that applies the exception stated in AES2027for eligible personnel costs, for contracts framed under the Law 17/2022, 5 September, article 23bis in the specified Entities of Public Sector". • Personnel costs will be eligible with a maximum of 36 PM in total for the personnel contracts altogether.

	• Duration of the contracts: during the whole or part of the duration of the project. **Other eligible costs:** Current costs, small scientific equipment, disposable materials, travelling expenses, complementary expenses (use of central and general research support services of the beneficiary entity), publication and dissemination of results and other costs as included in the AES 2027 that can be justified as necessary to carry out the proposed activities. **Overheads**, according to AES 2027 (25%) **Double funding of the same concept is not allowed.**
Funding of public-private partnerships allowed	Yes In the case of private partners, please be aware that ISCIII itself is only providing funds to private not-for-profit research institutions in the terms described at "Eligible Institutions" section.
Further guidance	• Principal Investigators (PI) **must have PhD degree.** • PI can only participate in **one project proposal** per call. • PIs belonging to an Accredited Health Research Institute (IIS), if also affiliated with any other institution, must apply only through the IIS. • The PI and all members of the research group must belong to the eligible institutions in the call. • Only one PI per beneficiary institution may be funded within the same proposal. • PIs that has an ongoing International Collaboration (PCIN) project of the same initiative (ERA PerMed and EP PerMed) and purpose that this call and that the project has an ending date after the 31st December 2027 will not be able to apply for this call. This incompatibility will affect only to the PI, and this incompatibility will not apply in the case that the PI participates as coordinator in the new application or in the ongoing project. • For additional incompatibilities please review AES2027. **Excluded personnel as Principal Investigator (PI):**

	• Those undergoing a postgraduate training in Health Specialization(MIR, EIR, FIR, QIR, BIR, PIR, RFIR). • Those undergoing research training (e.g. PhD students, or "Río Hortega" contracts). • Those undergoing postdoctoral training (e.g. "Sara Borrell" or "Juan de la Cierva" contracts). • Researchers contracted by a RICORs and platforms funded by ISCIII. **Maximum funding from ISCIII per awarded Spanish project:** • If a Spanish Partner requesting funding to the ISCIII is **NOT** the Coordinator of the transnational project: - **220.000€** (overheads included), if there is only one Spanish Partner requesting funding to the ISCIII in the proposal. - **275.000€** (overheads included), if there are two Spanish Partners requesting funding to the ISCIII in the proposal. • If a Spanish Partner requesting funding to the ISCIII **IS** the Coordinator of the transnational project: - **300.000€** (overheads included), if there is only one Spanish Partner in the proposal, acting as a coordinator. - **400.000€** (overheads included), if there is one Spanish Partner in addition to the Spanish Coordinator in the proposal, both requesting funding to the ISCIII. **Projects' duration:** from 24 months to 36 months. The level of funding will take into account the evaluation of the collaborative proposal, the scientific quality of the Spanish group, the added value of the international collaboration, and the financial resources available. **Requirements on data and repositories** • Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, and data instruments survey tools. Genomic data is understood as: association of complete genomes

(GWAS), matrixes of de polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the "ELIXIR Core Data Resources", or if non-European repositories or databases are to be used they must be certified by ELIXIR or the US National Center for Biotechnology Information (NCBI).

- ISCIII may not fund any project that may require a repository and/or a data base without a plan ensuring sustainability and decommissioning after the end of funding.

Requirements for clinical studies

Spanish groups that are involved on the performance of a clinical trial in the proposal, **are recommended to include** in their team a member from their scientific node of the EU Clinical Trials Network (SCReN or ECRIN-ERIC) or if it does not exist, a member from the personnel of their Clinical Research Supporting Platform of their institutions (UIC).

Acknowledgements

Any publication, database, product or event protected with IPR or not, resulting from the granted project must acknowledge "Award no. XX by Instituto de Salud Carlos III (ISCIII) through "La Acción Estratégica en Salud (Líneas Estratégicas de Investigación en Salud 2024-2027)" 2027 and within the EP PerMed Partnership" even after the end of the project, including other specific acknowledgments that could be requested by ISCIII to the granted project. For more information please see ISCIII's **ROR** here.

National phase

National applications will be required by ISCIII to the full proposal applicants according to the timeline established in the AES 2027. Due to administrative and legal regulations, the ISCIII establishes the **30th October 2027** as the national deadline for the decision on fundable project consortia which includes Spanish partners to be funded by

	ISCIII, which must present their national application in the period stated in the AES 2027 (probably September/October 2027). Any concerned applicant in a proposal for which no final decision has been made by the deadline end of 30/10/2027, could be declared not fundable by ISCIII. Submission of financial and scientific reports as specified by the call text at international level and additionally at the national level as specified by ISCIII's instructions (please check ISCIII's webpage). **Additional clause regarding the available grant:** After the evaluation process, depending on its budgetary availability, of the requested funding of the selected projects, and giving priority to projects requesting funding from ISCIII, ISCIII and other Spanish funding agencies may exchange applicants with each other in order to optimize the available funds, provided that the respective eligibility rules are met. Such applicants must submit the national phase of ISCIII, in time and form. In order to expedite the **eligibility check process**, it is mandatory that all the applicants submit the CVA-ISCIII of the PI. The CVA must clearly indicate the date of award of the PhD and, where applicable, any career interruptions or periods of reduced research activity (e.g. maternity, paternity or parental leave, caregiving responsibilities, long-term illness, or other relevant circumstances), including the start and end dates and the duration of each period. This document shall be submitted by the PI by electronic email before the proposal submission deadline to: **eppermed@isciii.es**.

Spain (Andalusia)

Funding Organisation	**Consejería de Presidencia, Sanidad y Emergencias de la Junta de Andalucía, (CPSEJA)**
Initial funding pre-commitment	250.000 €
Regional/National contact for the EP PerMed JTC2027	Alicia Milano Curto **ep.fps@juntadeandalucia.es**
Eligible institutions	Eligible organisation must be Andalusian Non-profit entities registered as Agents of the Andalusian Knowledge System (Registro de Agentes Andaluces del Conocimiento) with research and innovation activity in Biomedicine and Health Sciences, ie: Research managing foundations of the Andalusian Public Health System. Eligibility criteria established in **Orden de 10 de agosto de 2023**
Additional eligibility criteria	• Principal investigators must be linked through a civil servant, statutory or labour relationship with the applicant or performing centre. For Health Research Institutes (Institutos de Investigación Sanitaria, IIS), the link may be with any of the public or private law entities that are part of the IIS provided that the entity meets all the specific requirements determined in each action, and, in any case, be personnel assigned to the IIS. • More than one partner from Andalusia may participate in the same project. • A PI can only participate in one application per call. • For receiving regional funding, the final funding decision issued by the corresponding program's decision-making body must be accredited. • The duration of the projects shall be determined by the corresponding JTC. In any case, this period shall be stated in the award resolution.
Eligible costs	a. **Goods and services**: consumables, bibliographic material, equipment rentals, software licenses and external services.

	b. **Personnel costs**: specifically hired for the project, including salaries, employer Social Security contributions, legally established compensation and other duly justified expenses derived. c. **Travel, accommodation and subsistence** according to the maximum amounts of compensation for service established in Decree 54/1989, of March 21, on compensation for service of the Junta de Andalucía, exclusively for people who are part of the research group or hired under the funded project. Exceptionally, any expense outside these amounts, or for people other than those listed before, must be authorised by the granting body. d. **Registration fees for congresses or** conferences for the presentation and dissemination of the results. Publication costs e. **Other expenses** duly justified and necessary for carrying out the project. f. **Indirect costs** 21% g. **Subcontracting costs:** cannot exceed 50% of the funding and need prior authorization from the granting body. Nor Scientific aspects nor the management of the project should be subcontracted. The following are **not considered eligible** expenses - Equipment or Equipment repair and maintenance - Items or amounts that, after analysis, are not considered justified - Amounts paid to persons participating in the project, except for expenses necessary for special attention to patients that involve compensation for their participation in the project not derived from an employment relationship. *The sum of the funding or income received for the same purpose may in no case exceed the cost of the funded activity.*
Funding of public-private partnerships allowed	Yes., there can be private partners in the consortium (on own funding or e.g. asking financial support from another funding organisation.
Further guidance	The projects must respect the fundamental principles established in national and international declarations, protocols and conventions on research ethics, as well as respect the requirements established in national and regional legislation in the field of biomedical research, development and innovation, personal data protection and bioethics. *When the results are not susceptible to protection of industrial or intellectual property rights, the scientific publications resulting from the funding granted must be made available in open access, in accordance with article 37 of Law 14/2011, of June 1.*

Spain (Catalonia)

Funding Organisation	**Health Department – Generalitat de Catalunya, (DS-CAT) -** https://salutweb.gencat.cat/ca/inici
Initial funding pre-commitment	700.000 € Anticipated number of funded research groups: N° of projects: 3-4 Maximum funding per grant awarded to a project partner: 200.000 € per partner - 250.000 € per coordinator
Regional/National contact for the EP PerMed JTC2027	Directorate General for Health Research and Innovation Departament de Salut – Generalitat de Catalunya Carrer d'Aragó, 330-332, 08009 Barcelona Carme Pérez Tel: (+34) 935566103 peris@gencat.cat
Eligible institutions	Foundations managing research activities of both SISCAT and Public health centres who carry out research activity in Catalonia, including accredited Health Research Institutes and CERCA institutions.
Additional eligibility criteria	-
Eligible costs	• Personnel, Consumables, Core facilities, Travel (Max € 5,000 per year) • Other (direct costs). It is compulsory to include the cost of a financial audit certificate up to a maximum of € 2,000 • Overhead (Flat rate 21% calculated on direct costs) Equipment is not eligible
Funding of public-private partnerships allowed	Yes
Further guidance	peris@gencat.cat

Sweden (SRC)

Funding Organisation	**Swedish Research Council, (SRC) -** www.vr.se
Initial funding pre-commitment	1.500.000 €
Regional/National contact for the EP PerMed JTC2027	Abraham Mellkvist-Roos, +46 76 525 76 13, abmr@vr.se
Eligible institutions	The applicant must be an individual researcher holding a PhD. Only researchers at an administrating organisation approved by the Swedish Research Council may apply. Please refer to general applicant eligibility requirements found **here**. The applicant may not have an ongoing EP PerMed grant, or any other project grant concerning the same project concept, funded by the Swedish Reseach Council, at the start of the grant period.
Additional eligibility criteria	All Swedish applicants to the SRC must communicate with a SRC EP PerMed national contact person regarding their intention to participate in the call, before submission of the consortium application. Grant amount: Minimum 1 200 000 SEK (approximately 120 000 EUR) in total per Swedish partner in a project. The maximum amount of funding is 3 million SEK (approximately 300 000 EUR) in total for Swedish participation in a consortium with 1 Swedish partner. Maximum 4.5 million SEK (approximately 400 000 EUR) in total for Swedish participation in a consortium with 2 Swedish partners. The maximum amount of funding is 3,5 million SEK (approximately 350 000 EUR) in total for Swedish participation in a consortium with 1 Swedish coordinator. Maximum 5 million SEK (approximately 500 000 EUR) in total for Swedish participation in a consortium with 1 Swedish coordinator and 1 partner.

	Please note that the exchange rate 1 EUR = 10.00 SEK shall be used to calculate actual amounts applied for in the application. No funding of industrial partners. All Swedish project leaders participating in the call for support from the Swedish Research Council shall also submit a parallel application according to the Swedish Research Council's instructions. The application form and instructions how to submit the parallel application can be reached from the call text at the SRC website. Parallel application is a mandatory eligibility criterion. Failure to submit the parallel application to the Swedish Research Council before the deadline of the SRC call will result in the Swedish partner being declared ineligible
Eligible costs	The project grant may be used to fund all types of project-related costs, such as salaries (including your own salary, however no more than corresponding to the person's activity level in the project), running costs (such as consumables, travel including stays at research facilities, publication costs and minor equipment), premises and depreciation costs. The project grant may also be used to cover costs for patient advocacy organisations (PAO) part in the project. The costs that can be covered are the same as the above mentioned. Grants may not be used for scholarships. If a doctoral student participates, project funds may not be paid out as salary during teaching or other departmental duties.
Funding of public-private partnerships allowed	Yes, but the Swedish Research Council can only fund academic or clinical partners.
Further guidance	The SRC will only fund basic research projects and therefore invites Swedish applications that focus on early-stage research, provided that the overall project aligns with the call's scope on the development and validation of novel and innovative cell and gene therapies for personalised medicine.

Sweden (VINNOVA)

Funding Organisation	**Sweden´s Innovation Agency, (Vinnova)** - www.vinnova.se
Initial funding pre-commitment	2.250.000€ The total funding commitment is 25 million SEK (approximately 2.25M €). The maximum funding per consortium for Swedish participation is 3 million SEK for one Swedish partner and 5 million SEK for two Swedish partners.
Regional/National contact for the EP PerMed JTC2027	Casper Ullsten-Wahlund, +46 8 473 32 06, casper.ullsten-wahlund@vinnova.se
Eligible institutions	Universities, public research institutes, healthcare providers, enterprises and non-profit organisations. For details on rules for funding, see our webpage: **Rules for Vinnova's funding | Vinnova**
Additional eligibility criteria	The grants paid out by Vinnova must be administrated by a Swedish organisation. They need to be a Swedish legal entity with a Swedish organisation registration number. See Vinnova's general terms and conditions for funding **Vinnova's general terms and conditions for funding | Vinnova**
Eligible costs	Universities, public research institutes and public healthcare providers may receive funding of up to 100 % of their eligible costs, provided that the project is part of their non-economic activities. Vinnova follows the state aid rules for economic activities (enterprises). In this call enterprises can apply for either industrial research or experimental development. We can provide support according to GBER as well as the regulation on minor support (EU 2023/2831). If minor support is used, you need to include a minor support certificate. For more information on support for economic activities, see **Rules for funding | State aid for economic activities | Vinnova.**
Funding of public-private partnerships allowed	Yes

Further guidance	All consortia with Swedish applicants must submit a parallel application to Vinnova through our electronic submission system (one application per consortium). Deadline for this parallel application is approximately 1 week after the JTC submission deadline (see Vinnova's webpage for the JTC 2027 call). This applies to both the pre-proposal and the full proposal. Vinnova follows the principle of public access to official records according to Swedish law. Vinnova performs a confidentiality review before releasing any documents. For more information see: **Public documents and confidentiality | Vinnova.** A Swedish partner may apply for a maximum of 3 million SEK. If more than one Swedish partner applies for financing, the total amount cannot exceed 5 million SEK.

The Netherlands

Funding Organisation	**The Netherlands organisation for Health Research and Development (ZonMw)**
Initial funding pre-commitment	1.800.000 € Anticipated number of funded research projects: ≈ 6 Maximum funding per grant awarded to a project is 300.000 euro (= total amount for all Dutch partners participating in a consortium project).
Regional/National contact for the EP PerMed JTC2027	Rob Diemel, PhD Marcella de Boer, MSc Anna Wilbers, MSc EP-PerMed@zonmw.nl +31 70 349 5252
Eligible institutions	In this National Annex an applicant is defined as a researcher based in the Netherlands applying for funding (i.e. the Dutch part of an international consortium project). Applicants from the Netherlands may submit an application (i.e. participate in a consortium and request funding) if they have an employment relationship with the following Dutch organisations: • **Research organisations**, that meet the definition of a research organisation as referred to in EU state aid legislation may receive the research grant (Framework for state aid for research and development and innovation (2014/C 198/01), i.e. the R&D&I framework. In this call ZonMw is only able to fund applicants from research organisations based in the Netherlands belonging to category 'A. Academia' and 'B. Clinical/public health sector' as eligible for funding. This includes applicants from Dutch universities and university medical centres. Applicants belonging to category 'C. Private for-profit (enterprise) partners, e.g. SME and private non-profit partners' are not eligible for funding by ZonMw in this call.

	To be **eligible for ZonMw funding as a 'research organisation'** under the **European R&D&I framework**, the organisation's legal status must be established in advance to prevent the granting of unlawful state aid. This process follows two routes: Route 1: Direct entry (universities and university medical centres). These organisations do not undergo a qualification assessment and can submit a grant application directly: - Universities are designated as research organisations by operation of law, in line with the R&D&I framework. - University medical centres (UMCs) confirm their status as research organisations by submitting a **declaration**. The declaration must be issued by, or on behalf of, an authorised signatory registered with the Chamber of Commerce (KvK). The declaration form is only required in the full proposal stage and can be submitted via **kwalificatieOO@zonmw.nl** with **EP-PerMed@zonmw.nl** in cc before the submission deadline of the full proposals. Route 2: Eligibility assessment (Other organisations). Other organisations that aim to apply for funding as a research organisation must submit the following mandatory documents: - Completed 'Research Organisation Eligibility' **questionnaire**; - Digitally certified Extract from the Commercial Register (Chamber of Commerce/KvK), no older than 3 months; - Deed of incorporation and/or current articles of association; - Most recent complete, unpublished financial statements including an auditor's report (if legally required). Deadline for route 2: As soon as possible, but no later than 4 January 2027 by 14:00:00 CET via **kwalificatieOO@zonmw.nl**, stating the title of this call (EP PerMed JTC2027 CGT4PM) and with **EP-PerMed@zonmw.nl** in cc. Fast-track procedure:

	Organisations already recognised by ZonMw as a research organisation within the past 12 months, where its articles of association and activities remained unchanged since then, may use the fast-track procedure. The organisation must confirm this by submitting the designated declaration via **kwalificatieOO@zonmw.nl** with **EP-PerMed@zonmw.nl** Consequences of inability to confirm status: If the documents are not submitted on time, or if ZonMw cannot positively confirm the organisation's status as a re-search organisation, the organisation cannot submit an application in the capacity of a research organisation.
Additional eligibility criteria	• An applicant from the Netherlands may only request ZonMw funding for one project proposal (as part of an international consortium) in this call. • The Dutch part of an international consortium has a single national main contact person (i.e. Dutch Partner or Co-ordinator in the consortium project), who is responsible for scientific and financial management. • PhD student positions ('promovendus, AIO, OIO') cannot be applied for in this call.
Eligible costs	The **General Terms and Conditions Governing Grants** of ZonMw apply. **Costs:** Eligible costs of projects include: • Personnel costs • Bench fee • Costs of instruments and equipment to the extent and as long as they are used for the project • Other operational expenses: materials, travel costs for consortium meetings, costs for dissemination of results (implementation) of the project, open access costs with a maximum of 5000 € per project if the publication takes place according to the full golden route. Non-eligible costs of projects include: • Overhead is not allowed in most cases (e.g. university or University Medical Center).

	Personnel costs are funded in accordance with VSNU/NFU salary tables. **Budget formats and salary tables** can be downloaded from the ZonMw website. It is necessary to use these formats and salary tables in the preparation of the budget for the Dutch partners, both in the preproposal and full proposal stage. **State Aid**: No funding will be awarded by ZonMw if this would or could constitute unlawful state aid (section 107 of the Treaty on the Functioning of the EU (TFEU). Funding awarded to research organisation for the execution of non-economic research activities does not constitute state aid. Under this call, proposals may be submitted for projects involving fundamental research and industrial research while regarding the activities Research, Dissemination of results and/or Training, provided these falls within their primary task as research organisations. Note that accounting records must be kept separate.
Funding of public-private partnerships allowed	Yes, but ZonMw can only fund applicants from research organisations based in the Netherlands belonging to categories 'A. Academia' and 'B. Clinical/public health sector'.
Further guidance	The aforementioned General Terms and Conditions Governing Grants of ZonMw are applicable to the part of the project's budget covered by the grant from ZonMw. Any arrangements made regarding the part of the project's budget covered by the grant from ZonMw must comply with the General Terms and Conditions Governing Grants of ZonMw amended on 1 April 2022 and the European legislation on state aid. You must take account of **certain rights, conditions and obligations when applying for a ZonMw grant.** Dutch partner(s) in research projects selected for funding need to submit the proposal at the national level (**MijnZonMw**): • Submission of the full proposal to ZonMw will be carried out once the international evaluation and the ranking list have been established and endorsed by the Call Steering Committee. ZonMw will send a letter to invite the selected researcher(s) to submit the selected full proposal.

	• Dutch partner(s) in funded research projects have to comply with ZonMw procedures for granted projects (e.g. up-loading via 'MijnZonMw' - including the ZonMw budget format and reporting annually). Scientific personnel has to be appointed at a scientific institution in The Netherlands. Granted projects with a Dutch partner have to draw up and sign a Consortium Agreement in which also the intellectual property rights are incorporated. • A final draft version of the Consortium agreement (approved by all parties but not yet signed) will be required in order to assess conformity with applicable European state aid law, IP conditions and the ZonMw General Terms and Conditions. If the Consortium agreement is rejected, the funding by ZonMw cannot be granted. • Before the start of the granted project Dutch partner(s) in funded research projects needs to compose a data man-agement plan and complete key items to explain how to make the data collection from the Dutch part of the research project FAIR. • Every year an annual scientific report will be requested through the national submission system to inform ZonMw about the results of the Dutch partner(s) in funded research projects. An indication of the annual costs may be asked.

Türkiye

Funding Organisation	**The Scientific and Technological Research Council of Türkiye , (TÜBİTAK)**
Initial funding pre-commitment	400.000 €
Regional/National contact for the EP PerMed JTC2027	N. Selcan Turker, PhD 0090 3122981760 selcan.turker@tubitak.gov.tr
Eligible institutions	Applicants can apply from universities (public and private), research institutes, public and private organizations Foundations/Associations are not eligible. For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK. TÜBİTAK-funded costs of each grant shall be issued and managed by TÜBİTAK in accordance with the rules of TÜBİTAK 1071 Program
Additional eligibility criteria	No TRL restriction. TÜBİTAK national rules dictate a certain upper limit per project and per applicant type; however, these limits will be defined once the initial funding commitment is defined. Turkish applicants must add and indicate their Project Incentive Bonus and Institutional Share budgets on top of the national cost of the project itself. For further information, applicants should follow the announcements regarding this call on the official website of TUBITAK.
Eligible costs	Eligible types of funding under this programme are limited to personnel costs, travel and subsistence, equipment,

	consumables and subcontracting/services and a fixed amount of overhead budget per Turkish applicant. Projects intended to build infrastructure cannot be supported. For further information, applicants should follow the announcements regarding this call on the official website of TUBITAK and **Horizon Europe webpage dedicated to EP PerMed**.
Funding of public-private partnerships allowed	Yes
Further guidance	For further information, applicants should follow the announcements regarding this call on the official website of TUBITAK.